Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis

Najwa-Joelle Metri; Ali S Butt; Ava Murali; Genevieve Z Steiner-Lim; Chai K Lim

doi:10.1177/11786469231211184

. 2023 Nov 29;16:11786469231211184. doi: 10.1177/11786469231211184

Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis

Najwa-Joelle Metri ¹, Ali S Butt ¹, Ava Murali ³, Genevieve Z Steiner-Lim ^1,^2,^*, Chai K Lim ^3,^*,^✉

PMCID: PMC10687991 PMID: 38034059

Abstract

In this systematic review and meta-analysis, a normative dataset is generated from the published literature on the kynurenine pathway in control participants extracted from case-control and methodological validation studies. Study characteristics were mapped, and studies were evaluated in terms of analytical rigour and methodological validation. Meta-analyses of variance between types of instruments, sample matrices and metabolites were conducted. Regression analyses were applied to determine the relationship between metabolite, sample matrix, biological sex, participant age and study age. The grand mean concentrations of tryptophan in the serum and plasma were 60.52 ± 15.38 μM and 51.45 ± 10.47 μM, respectively. The grand mean concentrations of kynurenine in the serum and plasma were 1.96 ± 0.51 μM and 1.82 ± 0.54 μM, respectively. Regional differences in metabolite concentrations were observed across America, Asia, Australia, Europe and the Middle East. Of the total variance within the data, mode of detection (MOD) accounted for up to 2.96%, sample matrix up to 3.23%, and their interaction explained up to 1.53%; the latter of which was determined to be negligible. This review was intended to inform future empirical research and method development studies and successfully synthesised pilot data. The pilot data reported in this study will inform future precision medicine initiatives aimed at targeting the kynurenine pathway by improving the availability and quality of normative data.

Keywords: Tryptophan, kynurenine, normative data, metabolomics, meta-analysis, systematic review

Introduction

Tryptophan (TRP) metabolism and activity in the kynurenine pathway (KP) have been implicated in an array of conditions, including depressive, psychotic,¹ and metabolic disorders,² neurodegenerative,³ autoimmune,⁴ cardiovascular,⁵ kidney,⁶ and gastrointestinal diseases⁷ and cancer.⁸ This is due to their widespread roles in modulating both innate and adaptive immune responses and inflammation.^9,10 As a result, it has been suggested that the thorough analytical profiling of KP metabolites may improve patient care outcomes by revealing prognostic, diagnostic and theragnostic biomarkers.¹¹

Several meta-analyses have extensively profiled KP metabolites across various clinical cohorts within the plasma, serum, urine and cerebrospinal fluid.^1,12-15 Examples of the variables summarised include modes of detection (MODs) and relevant instrumentation, metabolites studied, sample matrices and geographical locations. Despite the breadth of these data, there is a lack of information on healthy and younger cohorts (eg, aged ⩽ 50 years) with normal metabolic functioning. Inter-sample variation in KP profiling is also less characterised. For example, studies have found that the information contained in peripheral samples, such as serum and urine, are statistically independent.¹⁶ Changes in the KP profile across the lifespan are even less characterised. These literature gaps are emphasised by the heterogeneity in methodological and analytical quality of the reported literature. Together, these factors mean that there is an absence of normative KP data, across the lifespan and across geographical regions, that is of high methodological and analytical rigour that may be referred to as a benchmark in future studies, clinical or otherwise.

The purpose of this study was to generate a set of KP normative values from the existing literature for the purpose of informing future biomarker investigations. This meta-analysis and systematic review therefore aimed to: (i) map the characteristics of studies reported within the literature, including MOD, metabolites studied, sample matrices and geographical location; (ii) calculate normative means for TRP and kynurenine (KYN) across these characteristics; (iii) critically appraise the methodologies and data reported within the literature, in terms of author-reported methodological validation and through an independent risk of bias assessment; (iv) ascertain variance in sensitivity between MOD; and (v) determine the relationship between metabolite, biofluid, age, sex and study year.

Methods and Materials

Study protocol

This systematic review and meta-analysis was prospectively registered with the PROSPERO International Database of Systematic Reviews on 26 December 2021 (#CRD42021293595), and followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (PRISMA).¹⁷ A review protocol was not prepared. It was anticipated that the review would provide insight into the evidence required to inform the outcomes of biomarker development research.

Search strategy

Initially, a scoping search was conducted using a comprehensive strategy to establish the breadth of the review on 15 November 2021. Based on this, a comprehensive search of articles was conducted on 4 electronic databases comprising PubMed, Web of Science, EMBASE and Scopus. Databases were searched for articles from peer-reviewed journals from the databases’ date of inception through to 27 December 2021. An example of the search algorithm from PubMed is described in Table 1. The same Medical Subject Headings (MeSH) and search strategy were applied across all 4 databases. However, minor adjustments were applied to allow for database-specific variations in the requirements for the search queries. Database alerts were set up to notify the authors of any new publications up until 1 October 2022 to allow for review finalisation, and citation searches on any reviews identified were performed. Authors were not contacted for missing data. Studies that did not report TRP or KYN as numerical values were excluded during the full-text screening phase.

Table 1.

Population, Intervention, Comparison, Outcomes, Study Design (PICOS) framework illustrating the systematic search strategy for PubMed.

Interest

The use of liquid chromatography, mass spectrometry, or ELISA assay techniques. MeSH terms or other synonyms included ‘Chromatography, Liquid’ OR ‘Mass Spectrometry’ OR ‘Enzyme-Linked Immunosorbent Assay’ OR ‘ELISA’

Outcome

The identification and quantification of tryptophan or kynurenine in human biofluids. MeSH terms or other synonyms included ‘Tryptophan’ OR ‘Kynurenine’

Study design

Observational, cross-sectional case-control study. Data relating to the biofluids of healthy control groups will be extracted from clinical studies, or from analytical studies focussed on healthy groups only. MeSH terms or other synonyms included ‘Blood’ OR ‘Serum’ OR ‘Plasma’ OR ‘Urine’ OR ‘Saliva’ OR ‘Sebum’ OR ‘Tears’ OR ‘Sweat’ OR ‘Cerebrospinal Fluid’ OR ‘Feces’ OR ‘Faeces’

Open in a new tab

Interest, outcome and study design searches were combined with the Boolean operator ‘AND’. Comparison terms were not specified due to the broad nature of the review.

Study selection

In total, 11 241 records were obtained from the systematic database search, indicating the feasibility of the review. All included studies were exported to a reference management software (EndNote™ X9; Thomson Reuters, CA, USA). Using EndNote, duplicate references were removed, and remaining titles and abstracts were screened against study inclusion and exclusion criteria by the primary reviewer (NJM). The titles and abstracts of the remaining records were screened and if there was any doubt regarding their eligibility, the full text was retrieved for clarification. Twenty percent of articles deemed eligible to the primary reviewer were then confirmed by 2 independent reviewers (CKL & GZS) to ensure inclusion criteria were met.

Eligibility criteria

Inclusion criteria for clinical and/or analytical studies included: (i) quantifying KP metabolites TRP and/or KYN in human biofluids including whole blood, blood serum, blood plasma, urine, saliva, sebum, tears, sweat, cerebrospinal fluid and faeces via targeted metabolomic approaches; (ii) observational cross-sectional case-control studies which included a healthy control group or analytical studies including only healthy adults with no known neurological, psychological or medical condition; (iii) reported in the English language; and (iv) using liquid chromatography (LC) coupled to mass spectrometry (MS), electron capture dissociation (ECD), spectroscopy, or enzyme-linked immunosorbent assays (ELISA).

Exclusion criteria for publications included: (i) conference proceedings and papers, editorials, letters, notes, short surveys, pre-prints, book chapters and book series; (ii) publications that explore TRP or KYN identification and/or quantification in nutritional supplements, animals, food products, or following an intervention such as TRP loading or depletion; and (iii) studies which utilise untargeted metabolomics due to potential imprecision in the metabolites characterised.

Data extraction

Data extraction was then completed (NJM, ASB, AM) and double-checked by a second independent reviewer (CKL, GZS, NJM, ASB, AM). Any disagreements were resolved by reviewing and discussing the articles amongst all co-authors (CKL, GZS, NJM, ASB, AM). Study characteristics were extracted including author, year of publication, MOD as per the instrument of detection, and the number of samples analysed. Concentrations of TRP and/or KYN in the biofluids of healthy adults were also extracted. In case-control studies, only data related to the control group were extracted and reported. The chromatographic conditions were extracted from eligible studies into standardised tables. To ensure the analytical rigour of the data, validation parameters of interest included: (i) determining the robustness of the method by testing the variation in the instrumental parameters; (ii) limits of quantification (LOQ); (iii) limits of detection (LOD); (iv) precision; (v) accuracy of the method via recoveries for determining true values; (vi) assessment of the analyte’s stability; (vii) calibration curve to test the response for a variety of standards; and (viii) the specificity such as matching the retention times of the samples and the standards.¹⁸

Risk of bias evaluation

As not one appropriate tool was available to assess the methodological quality of studies, this was evaluated using a combination of tools, including the QUADOMICS tool,¹⁹ the QUADAS tool²⁰ and the Joanna Briggs Institute (JBI) Checklist for Analytical Cross Sectional Studies.²¹ The adapted tool consisted of 6 items which account for the particular methodological challenges posed by metabolomic approaches (Supplemental Table S1). Items were either scores as Yes, No or NA/Unknown. Studies were then given an overall appraisal as either high quality or low quality by 3 members of the authorship team (NJM, ASB, AM).

Statistical analyses

Studies included in the meta-analysis (serum and plasma) were grouped via the MOD as per instrument of detection, by metabolite (TRP or KYN), by sample matrix and by geographical region (America, Asia, Australia, Europe, Middle East). Findings from pooled data were compared by utilising established estimation and approximation methods reported in the literature,²² this was largely related to the conversion of median and interquartile range to mean and standard deviation (SD). Weighted mean (±SD) concentrations of TRP and KYN were calculated per MOD, sample matrix and by geographical region reported. Variance in sensitivity between instruments was ascertained by a 2-way ANOVA followed by Tukey’s multiple comparison test. Only sample matrices with over 20 studies reported were included into the meta-analysis to ensure that there was enough statistical power to detect an effect. Sample matrices with <20 studies reported were synthesised and reported descriptively, with weighted means and pooled SDs from non-blood biofluids computed and summarised accordingly. To determine the relationship between metabolite, biofluid, age, sex and study year, an adjusted weighted-variance Ordinary Least Squares (OLS) regression analysis was performed. All statistical analyses were performed using GraphPad Prism v 9.0.0 (GraphPad Software, Inc., CA, USA) and Stata™ v17 (StataCorp, Texas, USA).

Results

The search strategy identified 11 241 publications. Following the application of the criteria, 531 full-text articles were assessed, of which 22.60% (N = 120) met the inclusion criteria (Figure 1). Serum and plasma were the only sample matrices with over 20 studies reported for subsequent inclusion in the meta-analysis. Due to small sample sizes (and consequently a high level of variability), urine, CSF, saliva, tears, faeces and whole blood studies were not synthesised descriptively and not meta-analysed.

Figure 1. — Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram detailing the search, identification, screening and eligibility processes.

Study characteristics

This meta-analysis reported on a grand total of 120 studies including 8089 participants (N = 120; n = 8089; Supplemental Table S2). Studies were reported from across 5 regions, including America, Asia, Australia, Europe and Middle East and 31 countries in total. Studies were most reported from China (23.33%; n = 28). The mean age across all studies was 47.35 ± 15.65 and of participants were female.

Regarding the quantification of TRP, a total of 8 sample matrices were reported within the literature. This included serum (n = 54), plasma (n = 48), urine (n = 15), cerebrospinal fluid (CSF; n = 6), saliva (n = 2), tears (n = 1), faeces (n = 1) and whole blood (n = 1). A total of 6 sample types were reported in the quantification of KYN: serum (n = 34), plasma (n = 33), urine (n = 7), CSF (n = 6), saliva (n = 2) and faeces (n = 1). The most common MOD across metabolites reported within the literature included mass spectrometry (MS; n = 80). Other modes of detection reported include fluorescence detection (FL), ultra-violet visible spectroscopy (UV-Vis), ELISA, photo diode array (PDA), ECD and electrochemiluminescence (ECL). The characteristics of the TRP and KYN quantification methods used in the included studies are described in Supplemental Table S3, including MOD, column phase and diameter, particle size, mobile phases, flow rate, injection volume, column temperature, programme time and detection wavelength (where applicable).

Risk of bias evaluation and method validation

Risk of bias varied across the reported studies and the breakdown of the appraisal is detailed for each study and item in Table 2. All citations are listed in Table 2. Over half of the included studies clearly defined their criteria for inclusion (59.17%; n = 71), while only 28.33% of studies (n = 34) described the study subjects and setting in detail. Majority of studies sufficiently described the type of sample (65.83%; n = 79) and the handling and pre-analytical processing of the samples (72.5%; n = 87). Only 34.17% (n = 41) of included studies sufficiently described their methodological conditions. Indeed, 84.17% (n = 101) of included studies reported their statistical analysis. Overall, 51.67% (n = 62) of studies were subjectively appraised to be of high quality.

Table 2.

Risk of bias across evaluation of included studies across the 6 bias domains and their overall rating.

Citation	Item 1	Item 2	Item 3	Item 4	Item 5	Item 6	Overall

Open in a new tab

Abbreviations: N, no; U, unclear; Y, yes. Colours: N, red; U, yellow; Y, green.

Item 1: Were the criteria for inclusion in the sample clearly defined?

Item 2: Were the study subjects and the setting described in detail?

Item 3: Was the sample type used fully described?

Item 4: Were the handling of specimens and pre-analytical procedures reported in sufficient detail and similar for the whole sample?

Item 5: Was the execution of the index test described in sufficient detail to permit replication of the test?

Item 6: Were uninterpretable or intermediate test results reported?

Reporting of independent method validation was highly varied (Table 3). Overall, 80.83% (n = 73) of studies reported at least one parameter of their independent methodological validation. Most commonly, LOD was reported in 44.17% (n = 53) studies. This was closely followed by the presentation of calibration curves (39.17%; n = 47). Robustness of the methodology was least commonly validated in only 10.83% (n = 13) of studies.

Table 3.

Reported method validation parameters of included studies, including specificity, calibration curve (CC), stability, accuracy, precision, LOD, LOQ and robustness.

Citation	Specificity	CC	Stability	Accuracy	Precision	LOD	LOQ	Robustness	Total (%)
Adrych et al, 2010	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Al Saedi et al, 2022	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Arnhard et al, 2018	✓	✓	✓	✓	✓	✓	✓	NR	7 (87.50)
Bai et al, 2021	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Barry et al, 2009	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Bassi et al, 2017	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Bizzarri et al, 1990	NR	✓	NR	✓	NR	✓	NR	NR	3 (37.50)
Buczko et al, 2007	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Calvani et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Capuron et al, 2011	NR	NR	NR	✓	NR	NR	NR	NR	1 (12.50)
Chang et al, 2018	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Chatterjee et al, 2019	✓	✓	NR	NR	NR	NR	NR	NR	2 (25.00)
Chen et al, 2019	✓	✓	✓	✓	✓	NR	✓	NR	6 (75.00)
Chen et al, 2010	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Chen et al, 2020	NR	✓	✓	✓	✓	NR	✓	✓	6 (75.00)
Cheng et al, 2015	NR	✓	✓	✓	✓	✓	✓	NR	6 (75.00)
Clarke et al, 2009	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Colle et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Crotti et al, 2019	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Cseh et al, 2019	NR	✓	NR	✓	✓	✓	✓	NR	5 (62.50)
Curto et al, 2016	NR	NR	NR	✓	✓	✓	✓	NR	4 (50.00)
Curto et al, 2016	NR	NR	NR	✓	✓	✓	✓	NR	4 (50.00)
Domingues et al, 2015	NR	✓	NR	✓	✓	NR	✓	NR	4 (50.00)
Doolin et al, 2018	NR	NR	NR	NR	NR	NR	✓	NR	1 (12.50)
Eniu et al, 2019	✓	✓	NR	NR	NR	✓	✓	NR	2 (25.00)
Fekkes et al, 1998	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Fitzgerald et al, 2008	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Frick et al, 2004	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Fukushima et al, 2014	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Furtado et al, 2017	NR	✓	NR	✓	✓	✓	✓	NR	5 (62.50)
Galla et al, 2021	✓	✓	✓	✓	✓	✓	✓	NR	7 (87.50)
Geisler et al, 2015	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Gevorkian et al, 2015	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Girgin et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Gomez-Gomez et al, 2017	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Gulaj et al, 2010	NR	NR	NR	NR	NR	✓	NR	NR	1 (12.50)
Hajsl et al, 2020	✓	✓	NR	✓	✓	NR	NR	NR	4 (50.00)
Han et al, 2018	✓	✓	✓	✓	✓	✓	NR	NR	6 (75.00)
Henykova et al, 2016	✓	NR	✓	✓	✓	✓	✓	NR	6 (75.00)
Huang et al, 2022	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Huang et al, 2021	NR	✓	NR	✓	✓	✓	✓	NR	5 (62.50)
Islam et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Jang et al, 2022	NR	✓	NR	NR	NR	✓	✓	NR	3 (37.50)
Kim et al, 2015	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Kim et al, 2009	NR	✓	NR	NR	NR	NR	NR	NR	1 (12.50)
Klatt et al, 2021	NR	NR	NR	✓	NR	NR	NR	NR	1 (12.50)
Koch et al, 1979	NR	✓	NR	NR	✓	NR	NR	NR	2 (25.00)
Krasnova et al, 2000	NR	NR	✓	NR	NR	✓	NR	NR	2 (25.00)
Kurgan et al, 2022	NR	NR	NR	NR	NR	✓	✓	NR	2 (25.00)
Leichtle et al, 2012	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Li et al, 2011	✓	✓	NR	NR	✓	✓	NR	NR	4 (50.00)
Lim et al, 2017	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Lionetto et al, 2021	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Liu et al, 2018	✓	✓	NR	✓	✓	✓	NR	NR	5 (62.50)
Lorite et al, 2007	NR	✓	✓	NR	NR	✓	✓	✓	5 (62.50)
Lu et al, 2019	NR	✓	NR	✓	✓	✓	NR	NR	4 (50.00)
Ma et al, 2009	NR	✓	NR	✓	✓	✓	NR	NR	4 (50.00)
Malhotra et al, 2017	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Meng et al, 2022	NR	✓	✓	NR	NR	✓	✓	✓	5 (62.50)
Michel et al, 2020	NR	NR	NR	✓	✓	✓	✓	NR	4 (50.00)
Mierzchala et al, 2020	NR	✓	✓	NR	NR	✓	✓	NR	4 (50.00)
Mu et al, 2012	✓	✓	NR	✓	✓	✓	✓	NR	6 (75.00)
Myint et al, 2007	NR	✓	✓	NR	NR	✓	✓	✓	5 (62.50)
Myint et al, 2007	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Nakatsukasa et al, 2011	NR	✓	✓	NR	NR	✓	✓	✓	5 (62.50)
Naz et al, 2019	✓	✓	NR	NR	NR	✓	✓	✓	6 (75.00)
Ogawa et al, 2018	✓	✓	NR	NR	NR	✓	✓	✓	6 (75.00)
Oh et al, 2017	✓	✓	✓	✓	✓	✓	✓	NR	7 (87.50)
Ohashi et al, 2013	NR	✓	NR	NR	NR	✓	✓	NR	3 (37.50)
Onesti et al, 2019	NR	NR	NR	NR	NR	✓	NR	NR	1 (12.50)
Palabiyik et al, 2016	✓	✓	NR	NR	NR	✓	✓	✓	5 (62.50)
Panitz et al, 2021	✓	✓	NR	NR	NR	✓	✓	✓	5 (62.50)
Pertovaara et al, 2005	✓	✓	NR	NR	NR	✓	✓	✓	5 (62.50)
Primiano et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Ren et al, 2011	✓	NR	NR	✓	✓	✓	NR	NR	4 (50.00)
Roca et al, 1999	✓	NR	✓	✓	NR	✓	✓	✓	6 (75.00)
Rodrigues et al, 2021	NR	NR	✓	✓	NR	NR	✓	NR	3 (37.50)
Ruoppolo et al, 2014	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Saito et al, 1979	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Saito et al, 2022	NR	✓	NR	✓	✓	NR	NR	NR	3 (37.50)
Sakaguchi et al, 2011	✓	✓	NR	✓	✓	✓	NR	NR	5 (62.50)
Schwieler et al, 2020	✓	✓	✓	✓	✓	✓	✓	NR	7 (87.50)
Shi et al, 2019	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Smolenska et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Sorgdrager et al, 2017	NR	NR	✓	✓	NR	✓	NR	NR	3 (37.50)
Sorgdrager et al, 2019	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Souissi et al, 2022	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Sousa et al, 2021	NR	✓	✓	✓	✓	✓	✓	NR	6 (75.00)
Sultana et al, 2012	✓	✓	✓	✓	✓	✓	✓	✓	8 (100)
Sun et al, 2021	NR	NR	NR	✓	✓	✓	✓	NR	4 (50.00)
Sun et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Suzuki et al, 2012	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Suzuki et al, 2010	NR	NR	NR	NR	✓	✓	✓	NR	3 (37.50)
Suzuki et al, 2011	NR	NR	NR	NR	✓	✓	✓	NR	3 (37.50)
Taherizadeh et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Tcherkas et al, 2001	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Tezcan et al, 2022	✓	NR	NR	NR	NR	NR	NR	NR	1 (12.50)
Tong et al, 2018	NR	✓	NR	✓	✓	NR	✓	NR	4 (50.00)
Trepci et al, 2021	NR	NR	NR	NR	NR	✓	✓	NR	2 (25.00)
Tuka et al, 2021	NR	✓	NR	✓	✓	✓	✓	✓	6 (75.00)
Uchikura et al, 2003	NR	NR	NR	✓	NR	✓	NR	NR	2 (25.00)
Valko et al, 2019	NR	✓	NR	✓	✓	✓	NR	NR	4 (50.00)
Van Faassen et al, 2019	✓	✓	✓	✓	✓	NR	✓	NR	6 (75.00)
Walser et al, 1993	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Wang et al, 2019	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Wang et al, 2018	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Widner et al, 2000	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Wu et al, 2022	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Wu et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Wu et al, 2018	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Xu et al, 2012	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Yan et al, 2017	NR	✓	✓	✓	✓	✓	✓	NR	6 (75.00)
Yao et al, 2010	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Yilmaz et al, 2020	✓	NR	NR	✓	NR	NR	NR	NR	2 (25.00)
Yoshitake et al, 2007	✓	✓	NR	✓	✓	✓	NR	NR	5 (62.50)
Zhang et al, 2020	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Zhao et al, 2011	✓	✓	✓	✓	✓	✓	NR	NR	6 (75.00)
Zhen et al, 2011	✓	✓	NR	✓	✓	✓	✓	NR	6 (75.00)
Zhou et al, 2022	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Zhou et al, 2019	NR	NR	NR	NR	NR	NR	NR	NR	0 (0.00)
Total (%)	35 (29.17)	47 (39.17)	23 (19.17)	43 (35.83)	39 (32.50)	53 (44.17)	44 (36.67)	13 (10.83)	NA

Open in a new tab

Abbreviations: ✓, reported; CC, calibration curve; LOD, limit of detection; LOQ, limit of quantification; NA, not applicable; NR, not reported.

Analysis of variance

All grand means, MOD means and region means for TRP and KYN are summarised in Table 4. Normative data was not able to be generated for certain variables due to small sample sizes and/or insufficient data. Variables to which this applies include: (a) KYN serum within the American region; (b) KYN serum as measured by FL; (b) KYN plasma as measured by FL; (c) TRP serum as measured by UV-Vis; (d) TRP plasma as measured by UV-Vis; (e) KYN serum as measured by ECD; and (f) KYN plasma as measured by ECD.

Table 4.

Normative data generated including grand mean concentrations (across all MODs and regions), region mean concentrations for TRP and KYN across serum and plasma, and MOD mean concentrations. Values presented are mean μM ± SD.

Mean	TRP serum	TRP plasma	KYN serum	KYN plasma
Grand mean	60.52 (15.38)	51.45 (10.47)	1.96 (0.51)	1.82 (0.54)
By region
America	49.66 (2.75)	34.68 (9.90)	NR	0.94 (0.24)
Asia	60.30 (8.69)	53.81 (9.95)	1.68 (0.43)	1.61 (0.34)
Australia	67.26 (11.19)	42.87 (8.51)	2.43 (0.59)	2.12 (0.52)
Europe	60.73 (10.66)	52.92 (12.06)	2.07 (0.52)	2.29 (0.73)
Middle East	54.01 (18.44)	34.82 (10.52)	1.56 (0.62)	1.53 (0.72)
By MOD
MS	60.39 (19.24)	50.07 (16.65)	1.90 (0.73)	1.91 (0.87)
FL	63.63 (15.36)	59.26 (15.02)	NR	NR
UV-Vis	NR	NR	2.22 (0.69)	1.95 (0.54)
ECD	63.04 (20.23)	26.49 (14.17)	NR	NR

Open in a new tab

Abbreviations: ECD, electron capture dissociation; FL, fluorescence detection; KYN, kynurenine; MOD, mode of detection; MS, mass spectrometry; NR, not reported; TRP, tryptophan; UV-Vis, ultraviolet-visible spectroscopy.

The weighted grand mean concentration of TRP in serum across all MODs was calculated to be 60.52 ± 15.38 μM (see Figure 2). Mean reported TRP serum content in America, Asia, Australia, Europe and the Middle East were 49.66 ± 2.75, 60.30 ± 8.69, 67.26 ± 11.19, 60.73 ± 10.66 and 54.01 ± 18.44 μM, respectively. Mean reported TRP content detected in the serum by MS, FL and ECD were 60.39 ± 19.24, 63.63 ± 15.36 and 63.04 ± 20.23 μM, respectively. In comparison, the weighted grand mean concentration of TRP in plasma was calculated to be 51.45 ± 10.47 μm (Figure 3). Mean reported TRP plasma content in America, Asia, Australia, Europe and the Middle East were 34.68 ± 9.90, 53.81 ± 9.95, 42.87 ± 8.51, 52.92 ± 12.06 and 34.82 ± 10.52 μM, respectively. Mean reported TRP content detected in the plasma by MS, FL and ECD were 50.07 ± 16.65, 59.26 ± 15.02 and 26.49 ± 14.17 μM, respectively. MOD accounts for 2.96% of the total variance seen within the data, F(2, 6542) = 114.16, P < .001. Sample matrix accounted for 3.23% of the total variance seen within the data, F(1, 6542) = 248.93, P < .001. The interaction between MOD and sample matrix accounted for 1.53% of the total variance seen in the data F(2, 6542) = 58.94, P < .001.

Figure 3. — Forest plot depicting weighted grand mean concentrations [95%CI] of TRP in plasma (μM) for each study together with region mean concentrations.

The weighted grand mean concentration of KYN in serum across all MODs was calculated to be 1.96 ± 0.51 μM (Figure 4). Mean reported KYN serum content in Asia, Australia, Europe and the Middle East were 1.68 ± 0.43, 2.43 ± 0.59, 2.07 ± 0.52 and 1.56 ± 0.62 μM, respectively. Mean reported KYN content detected in the serum by MS and UV-Vis were 1.90 ± 0.73 μM and 2.22 ± 0.69 μM, respectively. In comparison, the weighted grand mean concentration of KYN in plasma across all MODs was calculated to be 1.82 ± 0.54 μM (Figure 5). Mean reported KYN plasma content in America, Asia, Australia, Europe and the Middle East were 0.94 ± 0.24, 1.61 ± 0.34, 2.12 ± 0.52, 2.29 ± 0.73 and 1.53 ± 0.72 μM, respectively. Mean reported KYN content detected in the plasma by MS and UV-Vis were 1.91 ± 0.87 μM and 1.95 ± 0.54 μM, respectively. MOD accounts for 1.30% of the total variance seen within the data, F(1, 3868) = 51.37, P < .001. Sample matrix accounted for 0.71% of the total variance seen within the data, F(1, 3868) = 27.96, P < .001. The interaction between MOD and sample matrix accounted for 0.79% of the total variance seen in the data, F(1, 3868) = 31.25, P < .001.

Figure 5. — Forest plot depicting weighted grand mean concentrations [95%CI] of KYN in plasma (μM) for each study together with region mean concentrations.

Regression analyses

Outcomes from the adjusted weighted-variance OLS regressions including non-standardised β-coefficients and 95%CIs are listed in Table 5, for TRP and KYN concentrations in serum, plasma and blood, assessing predictors of biological sex, age and study year, with P-values for statistically significant outcomes bolded. In summary, female sex, age and study year were negatively correlated with TRP concentrations measured within the serum. Age and study year were also negatively correlated with TRP concentrations measured within the plasma, although no significant interaction was observed between biological sex and the concentrations measured. Across both serum and plasma, biological sex, age and study year were correlated with TRP concentrations measured within the serum. These trends were repeated when considering KYN, although age was positively correlated with KYN concentrations. Interestingly, biological sex was not correlated with both TRP and KYN concentrations within the plasma.

Table 5.

Adjusted weighted-variance OLS regression analyses for TRP and KYN. TRP blood and KYN blood are the pooled sample sizes of serum and plasma studies.

	β-Coeff [95%CI]	P
TRP serum
Proportion female^*	−0.22 [−0.39, −0.05]	.012
Age	−0.20 [−0.38, −0.01]	.036
Study year	−1.37 [−1.67, −1.08]	<.001
TRP plasma
Proportion female^*	−0.03 [−0.08, 0.02]	.266
Age	−0.74 [−0.86, −0.61]	<.001
Study year	−1.58 [−1.87, −1.30]	<.001
TRP blood
Proportion female^*	−0.14 [−0.19, −0.09]	<.001
Age	−0.55 [−0.65, −0.45]	<.001
Study year	−1.35 [−1.55, −1.16]	<.001
KYN serum
Proportion female^*	−0.05 [−0.05, −0.04]	<.001
Age	0.01 [0.00, 0.01]	.002
Study year	−0.08 [−0.08, −0.07]	<.001
KYN plasma
Proportion female^*	−0.00 [−0.00, 0.00]	.431
Age	0.02 [0.01, 0.02]	<.001
Study year	−0.08 [−0.10, −0.07]	<.001
KYN blood
Proportion female^*	−0.02 [−0.02, −0.02]	<.001
Age	0.01 [0.01, 0.01]	<.001
Study year	−0.11 [−0.12, −0.11]	<.001

Open in a new tab

Proportion female refers to the percentage of female participants as a proportion of the total sample size. This suggests that a positive β-Coeff value would indicate that as the proportion of female participants increases, metabolite concentrations increase and vice versa. A negative β-Coeff would therefore indicate higher metabolite concentrations in male participants.

Abbreviations: KYN, kynurenine; OLS, ordinary least squares; TRP, tryptophan.

Non-blood sample matrices

All grand means for non-blood sample matrices are summarised in Table 6. TRP concentrations were reported in the urine (n = 15), CSF (n = 6), saliva (n = 2), tears (n = 1), faeces (n = 1) and whole blood (n = 1); while KYN concentrations were reported in the urine (n = 7), CSF (n = 6), saliva (n = 2) and faeces (n = 1).

Table 6.

Normative data generated for TRP and KYN concentrations across urine, CSF, saliva, tears, faeces and whole blood. Values presented are mean μM ± SD.

Sample matrix	TRP	KYN
Urine	16.94 (20.40)	2.48 (4.41)
CSF	1.85 (0.22)	0.13 (0.03)
Saliva	0.77 (0.82)	0.05 (0.01)
Tears	17.10 (3.90)	NR
Faeces	0.23 (0.18)	0.00 (0.00)
Whole blood	32.32 (3.7)	NR

Open in a new tab

Abbreviations: CSF, cerebrospinal fluid; KYN, kynurenine; NR, not reported; TRP, tryptophan.

Discussion

Precision medicine initiatives are currently limited by the availability and quality of the data summarising the KP profile.^143,144 The current study addressed this gap by systematically mapping study characteristics according to MOD, metabolites studied, sample matrices and geographical location, and by calculating normative means of TRP and KYN concentrations. The methodologies and risk of bias reported within the literature were also critically appraised, the variance between MODs was determined based on the instrument reported, and the relationship between metabolite, biofluid, age, sex and study year were assessed.

FL and UV-Vis are suitable MODs for the analytical profiling of KP metabolites despite their less frequent use in the literature. The TRP and KYN metabolomic studies reported within this meta-analysis indicate that the most common MOD is MS (N = 80). High resolution MS is commonly used in lipidomics,¹⁴⁵ proteomics¹⁴⁶ and precision pharmacology.¹⁴⁷ MS offers significant advantages in terms of sensitive analytical profiling,¹⁴⁸ and FL and UV-Vis MODs are limited in their sensitivity by the light-emitting capacity of the metabolite.¹⁴⁹ Nonetheless, the photophysical properties of TRP and KYN are well-characterised, and TRP and KYN are moderate emitters of intrinsic fluorescence and thus suitable for light-based detection.¹⁵⁰ Moreover, concentrations of TRP and KYN within the serum, plasma and urine are mostly within the micromolar range.^24-26 This suggests that FL and UV-Vis MODs, that are generally less favoured in terms of sensitivity, may be suitable cost-effective alternatives for these sample matrices.^148,149 Studies aiming to quantify TRP and KYN in other sample matrices such as tears or saliva, where the concentration detected is generally lower,⁸⁷ benefit from the sensitive analytical profiling of MS.¹⁴⁸ Certain MOD averages reported within this meta-analysis, such as ECD, indicate extreme outliers. This may be due to the small number of studies reported within the literature, all of which vary in sample size. Further, the interaction between MOD and sample matrix accounted for 0.79% of the total variance, suggesting that choice of MOD should not affect the comparability of results between serum and plasma. Considering that the intra-coefficient and inter-coefficient of variation for a single assay will typically vary within an acceptable range of 3%-7% and the <1% variation between sample types, the interaction between sample type and MOD observed here at the population level is negligible.

TRP and KYN concentrations vary based on region, most likely due to genetic and dietary factors.¹⁵¹ Here, across serum and plasma TRP and KYN concentrations, American and Middle Eastern data were consistently lower than the grand population mean. It is generally well-understood that high protein and fat intake may increase the availability of TRP in the plasma and hence upregulate the KP, and vice versa.¹⁵¹ Differences in KP concentrations, including lower levels of TRP and KYN, may underpin heightened disease risk, including skeletal muscle atrophy,¹⁵² cognitive decline¹⁵² and higher mortality in cardiovascular disease,¹⁵³ for example.

The sample matrices reported in this study suggest that there is a growing interest in minimally invasive sample types. The majority (66.67%) of the TRP urine papers have been published since 2015,^{28,53,57,63,90,96,110,124,134,136} while all included TRP saliva studies were published within this timeframe.^38,71 Saliva metabolomics is an emerging field of research due to the diversity of metabolites present and the relative ease in sampling including decentralised approaches.¹⁵⁴ Interest in saliva metabolomic profiling has also piqued due to reductions in the LOD of MS technologies and thus the improving analytical sensitivity.¹⁴⁸ Urine is of interest in the field of biomarker discovery research as it is non-invasive, readily obtained in large quantities, and generally has high patient compliance.¹⁵⁵ Urine may provide a relatively richer matrix for analysis, given that concentrations of metabolites are often higher in the urine (due to their excretion) when compared to serum.¹⁵⁶ This indicates that urine may be more susceptible to metabolic changes when compared to the serum.¹⁵⁶ Saliva and urine therefore present rich matrices for simple disease diagnostics in a minimally invasive and generally inexpensive manner.¹⁵⁴ However, the relevance of these peripheral sample types in specific diseases warrants further investigation. Recent literature has established a relationship between cognitive function and gut dysbiosis,¹⁵⁷ suggesting that peripheral-based biomarkers may be relevant sample matrices with respect to neurodegenerative diseases. The relationship between peripheral and central KP markers for neurodegeneration is supported by studies showing that plasma concentrations of KP metabolites KYN, 3-HAA, AA and PA are significantly correlated with their respective CSF levels.¹⁵⁸

There are significant limitations in the accuracy and sensitivity of KP metabolomics approaches. Overall, 80.83% (N = 73) of studies reported at least one parameter of their independent methodological validation, chosen in compliance with the guidelines for pharmaceutical and biotechnology industries.¹⁸ Despite the dedicated experimental designs for robustness testing of LC-MS instruments reported within the literature,¹⁵⁹ this parameter was only reported in 10.83% of the included studies.

The risk of bias appraisal questioned the reliability of the results reported here. Overall, only 51.67% of studies included in this meta-analysis were subjectively appraised to be of high quality. This was largely linked to poor reporting of methodological conditions (only reported in 34.17% of included studies). It is generally acknowledged that MS data presents various complexities linked to the various independently developed acquisition methods, diverse workflows, and non-standardised manual curation.¹⁶⁰ The studies which were appraised to be of low quality often reported significant deviations from the calculated grand population mean.^{43,60,69,84,130} Nonetheless, this meta-analysis featured a very large sample size and TRP and KYN means are generally considered statistically reliable.

TRP and KYN concentrations were lower in female than male participants across both serum and plasma, an observation typically observed in younger healthy cohorts.⁵⁴ With advancing age, TRP concentrations decreased, reflecting increased degradation of TRP in older age,⁵⁰ while KYN concentrations increased. Recent studies conducted in older adults identified the same pattern of results,^161,162 indicating the close link between age and metabolic activity related to TRP and the KP. Findings may help with the accurate profiling of the KP metabolome in diseases which show sex and age specific differences, such as AD.¹⁶³ The decrease in TRP concentrations and elevated KYN concentrations suggest increased KP activation with advanced age. Upregulation of the KP may be linked to oxidative stress and neuroinflammation, pathologies linked to ageing.¹⁶⁴

Strengths of this study include a broad eligibility criteria and thorough search strategy that detected ample records; the inclusion of only normative data; the inclusion of only targeted metabolomics data to ensure that precise metabolites have been profiled; and rigorous appraisal of the risk of bias and the validation parameters applied for methodological appraisal. Furthermore, this study had a large sample size (n = 8089) of relatively younger (⩽50 years) adults (47.35 ± 15.65), suggesting that it is statistically powered to detect accurate results. Limitations include an unequal distribution of sexes, with 77.67% of participants being of female biological sex. Moreover, meta-analyses were limited to serum and plasma data due to insufficient sample size in other minimally invasive sample types. This study was also limited to only TRP and KYN concentrations, and future studies should seek to assess other biologically active KP metabolites. Majority of the normative data presented in the literature is investigated within cohorts that are deemed healthy as screened against a singular health concern. This suggests that there may be some ambiguities in classifying normative data within the literature. Nonetheless, this review was intended to inform future empirical research and method development studies and successfully synthesised pilot data.

Future multi-site studies should seek to investigate and control for the relationship between geographical location and metabolite concentration, as well as clarify the relationship between study age and findings. Normative data should also be grouped into age and biological sex-specific brackets to ensure accuracy and specificity when being used for biomarker purposes. Specifically, studies should seek to report the metabolic profile of males and females separately. Moreover, future method development studies should seek to standardise acquisition methods, workflows and manual curation methods to improve the comparability of methodologies before moving into clinical and at-risk cohorts. Finally, future studies should consider comprehensively profiling the full KP metabolome within an array of biological sample matrices and should seek to identify any correlations between samples to determine the diagnostic accuracy of the KP across a range of inflammatory health conditions.

Supplemental Material

sj-docx-1-try-10.1177_11786469231211184 – Supplemental material for Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis

Click here for additional data file.^{(85.5KB, docx)}

Supplemental material, sj-docx-1-try-10.1177_11786469231211184 for Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis by Najwa-Joelle Metri, Ali S Butt, Ava Murali, Genevieve Z Steiner-Lim and Chai K Lim in International Journal of Tryptophan Research

sj-docx-2-try-10.1177_11786469231211184 – Supplemental material for Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis

Click here for additional data file.^{(31.5KB, docx)}

Supplemental material, sj-docx-2-try-10.1177_11786469231211184 for Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis by Najwa-Joelle Metri, Ali S Butt, Ava Murali, Genevieve Z Steiner-Lim and Chai K Lim in International Journal of Tryptophan Research

Footnotes

Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: GZS’s contribution was supported by funding from a National Health and Medical Research Council (NHMRC) Investigator Grant (APP1195709). Other than this, the authors received no financial support for the research, authorship, and/or publication of this article.

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: As a medical research institute, NICM Health Research Institute receives research grants and donations from foundations, universities, government agencies, individuals, and industry. Sponsors and donors provide untied funding for work to advance the vision and mission of the Institute. The project that is the subject of this article was not undertaken as part of a contractual relationship with any organisation other than the funding declared. NJM, ASB, and GZS are employed by NICM, but have no conflicts to declare with respect to the research, authorship, and/or publication of this article.

Author Contributions: NJM, GZS and CKL conceptualised the study and created the search strategy. NJM conducted the database searches and screened all articles. 10 % of articles screened were double-checked by ASB and AM to ensure concordance between co-authors. Data extraction was completed by NJM, ASB, and AM. Data extraction was double-checked by NJM, GZS, and CKL. Data were analysed and interpreted by CKL and NJM.

The manuscript was prepared by NJM, GZS, and CKL.

Supplemental Material: Supplemental material for this article is available online.

References

1. Marx W, McGuinness AJ, Rocks T, et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26:4158-4178. [DOI] [PubMed] [Google Scholar]
2. Qi Q, Li J, Yu B, et al. Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies. Gut. 2022;71:1095-1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
3. Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134-141. [DOI] [PubMed] [Google Scholar]
4. Krupa A, Kowalska I. The kynurenine pathway-new linkage between innate and adaptive immunity in autoimmune endocrinopathies. Int J Mol Sci. 2021;22:9879. [DOI] [PMC free article] [PubMed] [Google Scholar]
5. Zhang D, Ning J, Ramprasath T, et al. Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis. Nat Commun. 2022;13:6371. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
6. Nguyen DT, Kleczko EK, Dwivedi N, et al. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023;8:e154773. [DOI] [PMC free article] [PubMed] [Google Scholar]
7. Sofia MA, Ciorba MA, Meckel K, et al. Tryptophan metabolism through the kynurenine pathway is associated with endoscopic inflammation in ulcerative colitis. Inflamm Bowel Dis. 2018;24:1471-1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896. [DOI] [PubMed] [Google Scholar]
9. Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
10. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364:82-90. [DOI] [PubMed] [Google Scholar]
11. Beger RD, Dunn W, Schmidt MA, et al.; for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics. 2016;12:149-215. [DOI] [PMC free article] [PubMed] [Google Scholar]
12. Ogyu K, Kubo K, Noda Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16-25. [DOI] [PubMed] [Google Scholar]
13. Almulla AF, Vasupanrajit A, Tunvirachaisakul C, et al. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry. 2022;27: 3679-3691. [DOI] [PubMed] [Google Scholar]
14. Cao B, Chen Y, Ren Z, et al. Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;123:203-214. [DOI] [PubMed] [Google Scholar]
15. Hunt C, Macedo E, Cordeiro T, Suchting R, et al. Effect of immune activation on the kynurenine pathway and depression symptoms – a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;118:514-523. [DOI] [PMC free article] [PubMed] [Google Scholar]
16. Lau CE, Siskos AP, Maitre L, et al. Determinants of the urinary and serum metabolome in children from six European populations. BMC Med. 2018;16: 202-219. [DOI] [PMC free article] [PubMed] [Google Scholar]
17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
18. Haider SI. Validation Standard Operating Procedures: A Step by Step Guide for Achieving Compliance in the Pharmaceutical, Medical Device, and Biotech Industries. CRC Press; 2006. [Google Scholar]
19. Lumbreras B, Porta M, Márquez S, et al. QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies. Clin Biochem. 2008;41:1316-1325. [DOI] [PubMed] [Google Scholar]
20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
21. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Analytical Cross Sectional Studies. North Adelaide, Australia The Joanna Briggs Institute; 2017. [Google Scholar]
22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. [DOI] [PMC free article] [PubMed] [Google Scholar]
23. Adrych K, Smoczynski M, Stojek M, et al. Decreased serum essential and aromatic amino acids in patients with chronic pancreatitis. World J Gastroenterol. 2010;16:4422-4427. [DOI] [PMC free article] [PubMed] [Google Scholar]
24. Al Saedi A, Chow S, Vogrin S, Guillemin GJ, Duque G. Association between tryptophan metabolites, physical performance, and frailty in older persons. Int J Tryptophan Res. 2022;15. [DOI] [PMC free article] [PubMed] [Google Scholar]
25. Arnhard K, Pitterl F, Sperner-Unterweger B, et al. A validated liquid chromatography-high resolution-tandem mass spectrometry method for the simultaneous quantitation of tryptophan, kynurenine, kynurenic acid, and quinolinic acid in human plasma. Electrophoresis. 2018;39:1171-1180. [DOI] [PubMed] [Google Scholar]
26. Bai JH, Zheng YL, Yu YP. Urinary kynurenine as a biomarker for Parkinson’s disease. Neurol Sci. 2021;42:697-703. [DOI] [PubMed] [Google Scholar]
27. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol. 2009;23:287-294. [DOI] [PubMed] [Google Scholar]
28. Bassi R, Niewczas MA, Biancone L, et al. Metabolomic profiling in individuals with a failing kidney allograft. PLoS One. 2017;12:e0169077. [DOI] [PMC free article] [PubMed] [Google Scholar]
29. Bizzarri M, Catizone A, Pompei M, et al. Determination of urinary tryptophan and its metabolites along the nicotinic acid pathway by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 1990;4:24-27. [DOI] [PubMed] [Google Scholar]
30. Buczko P, Tankiewicz-Kwedlo A, Buraczewska A, Pawlak D, Mysliwiec M. Accumulation of kynurenine pathway metabolites in salive and plasma of uremic patients. Pharmacol Rep. 2007;59:199-204.17556798 [Google Scholar]
31. Calvani R, Rodriguez-Mañas L, Picca A, et al. Identification of a circulating amino acid signature in frail older persons with type 2 diabetes mellitus: results from the metabofrail study. Nutrients. 2020;12:199. [DOI] [PMC free article] [PubMed] [Google Scholar]
32. Capuron L, Schroecksnadel S, Féart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70:175-182. [DOI] [PubMed] [Google Scholar]
33. Chang KH, Cheng ML, Tang HY, et al. Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson’s disease. Mol Neurobiol. 2018;55:6319-6328. [DOI] [PubMed] [Google Scholar]
34. Chatterjee P, Zetterberg H, Goozee K, et al. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease. J Neuroinflammation. 2019;16:186. [DOI] [PMC free article] [PubMed] [Google Scholar]
35. Chen Y, Chen H, Shi G, et al. Ultra-performance liquid chromatography-tandem mass spectrometry quantitative profiling of tryptophan metabolites in human plasma and its application to clinical study. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1128. [DOI] [PubMed] [Google Scholar]
36. Chen Y, Stankovic R, Cullen KM, et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18:132-142. [DOI] [PubMed] [Google Scholar]
37. Chen Z, Lin F, Ye X, et al. Simultaneous determination of five essential amino acids in plasma of hyperlipidemic subjects by UPLC-MS/MS. Lipids Health Dis. 2020;19:52. [DOI] [PMC free article] [PubMed] [Google Scholar]
38. Cheng F, Wang Z, Huang Y, Duan Y, Wang X. Investigation of salivary free amino acid profile for early diagnosis of breast cancer with ultra performance liquid chromatography-mass spectrometry. Clin Chim Acta. 2015;447:23-31. [DOI] [PubMed] [Google Scholar]
39. Clarke G, Fitzgerald P, Cryan JF, et al. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009;9:6. [DOI] [PMC free article] [PubMed] [Google Scholar]
40. Colle R, Masson P, Verstuyft C, et al. Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: a case-control study. Psychiatry Clin Neurosci. 2020;74:112-117. [DOI] [PubMed] [Google Scholar]
41. Crotti S, Bedin C, Bertazzo A, et al. Tryptophan metabolism as source of new prognostic biomarkers for FAP patients. Int J Tryptophan Res. 2019;12. [DOI] [PMC free article] [PubMed] [Google Scholar]
42. Cseh EK, Veres G, Szentirmai M, et al. HPLC method for the assessment of tryptophan metabolism utilizing separate internal standard for each detector. Anal Biochem. 2019;574:7-14. [DOI] [PubMed] [Google Scholar]
43. Curto M, Lionetto L, Negro A, et al. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain. 2015;17:47. [DOI] [PMC free article] [PubMed] [Google Scholar]
44. Curto M, Lionetto L, Negro A, et al. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. J Headache Pain. 2015;17:27. [DOI] [PMC free article] [PubMed] [Google Scholar]
45. Domingues DS, Crevelin EJ, de Moraes LA, et al. Simultaneous determination of amino acids and neurotransmitters in plasma samples from schizophrenic patients by hydrophilic interaction liquid chromatography with tandem mass spectrometry. J Sep Sci. 2015;38:780-787. [DOI] [PubMed] [Google Scholar]
46. Doolin K, Allers KA, Pleiner S, et al. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology. 2018;95:8-17. [DOI] [PubMed] [Google Scholar]
47. Eniu DT, Romanciuc F, Moraru C, et al. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression. Scand J Clin Lab Invest. 2019;79:17-24. [DOI] [PubMed] [Google Scholar]
48. Fekkes D, van der Cammen TJ, van Loon CP, et al. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm. 1998;105:287-294. [DOI] [PubMed] [Google Scholar]
49. Fitzgerald P, Cassidy Eugene M, Clarke G, et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil. 2008;20: 1291-1297. [DOI] [PubMed] [Google Scholar]
50. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem. 2004;37:684-687. [DOI] [PubMed] [Google Scholar]
51. Fukushima T, Iizuka H, Yokota A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum d-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014;9:e101652. [DOI] [PMC free article] [PubMed] [Google Scholar]
52. Furtado DZS, de Moura Leite FBV, Barreto CN, et al. Profiles of amino acids and biogenic amines in the plasma of Cri-du-Chat patients. J Pharm Biomed Anal. 2017;140:137-145. [DOI] [PubMed] [Google Scholar]
53. Galla Z, Rácz G, Grecsó N, et al. Improved LC-MS/MS method for the determination of 42 neurologically and metabolically important molecules in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1179. [DOI] [PubMed] [Google Scholar]
54. Geisler S, Mayersbach P, Becker K, et al. Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. Pteridines. 2015;26:31-36. [Google Scholar]
55. Rosas HD, Doros G, Bhasin S, et al. A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease. Ann Clin Transl Neurol. 2015;2: 756-768. [DOI] [PMC free article] [PubMed] [Google Scholar]
56. Gürcü S, Girgin G, Yorulmaz G, et al. Neopterin and biopterin levels and tryptophan degradation in patients with diabetes. Sci Rep. 2020;10:17025. [DOI] [PMC free article] [PubMed] [Google Scholar]
57. Gomez-Gomez A, Marcos J, Aguilera P, To-Figueras J, Pozo OJ. Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:347-354. [DOI] [PubMed] [Google Scholar]
58. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer’s disease patients. Adv Med Sci. 2010;55:204-211. [DOI] [PubMed] [Google Scholar]
59. Hajsl M, Hlavackova A, Broulikova K, et al. Tryptophan metabolism, inflammation, and oxidative stress in patients with neurovascular disease. Metabolites. 2020;10. [DOI] [PMC free article] [PubMed] [Google Scholar]
60. Han M, Xie M, Han J, et al. Development and validation of a rapid, selective, and sensitive LC–MS/MS method for simultaneous determination of d- and l-amino acids in human serum: application to the study of hepatocellular carcinoma. Anal Bioanal Chem. 2018;410:2517-2531. [DOI] [PubMed] [Google Scholar]
61. Hényková E, Vránová HP, Amakorová P, et al. Stable isotope dilution ultra-high performance liquid chromatography-tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid. J Chromatogr A. 2016;1437:145-157. [DOI] [PubMed] [Google Scholar]
62. Huang J, Zhang P, Zhou Y, et al. Serum kynurenine metabolites might not be associated with risk factors of treatment-resistant schizophrenia. J Psychiatr Res. 2022;145:339-346. [DOI] [PubMed] [Google Scholar]
63. Huang R, Shen K, He Q, et al. Metabolic profiling of urinary chiral amino-containing biomarkers for gastric cancer using a sensitive chiral chlorine-labeled probe by HPLC-MS/MS. J Proteome Res. 2021;20:3952-3962. [DOI] [PubMed] [Google Scholar]
64. Islam MR, Ali S, Karmoker JR, et al. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020;20:333. [DOI] [PMC free article] [PubMed] [Google Scholar]
65. Jang JH, Yoo SY, Park YE, et al. The kynurenine pathway and mediating role of stress in addictive disorders: A focus on alcohol use disorder and internet gaming disorder. Front Pharmacol. 2022;13. [DOI] [PMC free article] [PubMed] [Google Scholar]
66. Kim HJ, Jang SH, Ryu JS, et al. The performance of a novel amino acid multivariate index for detecting lung cancer: a case control study in Korea. Lung Cancer. 2015;90:522-527. [DOI] [PubMed] [Google Scholar]
67. Kim YK, Myint AM, Verkerk R, et al. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology. 2009;59:123-129. [DOI] [PubMed] [Google Scholar]
68. Klatt S, Doecke JD, Roberts A, et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. Parkinsons Dis. 2021;7:94. [DOI] [PMC free article] [PubMed] [Google Scholar]
69. Koch DD, Kissinger PT. Determination of tryptophan and several of its metabolites in physiological samples by reversed-phase liquid chromatography with electrochemical detection. J Chromatogr. 1979;164:444-455. [PubMed] [Google Scholar]
70. Krasnova IN, Kartsova LA, Cherkas YV. Determination of amino acids in human blood serum by reversed-phase high-performance liquid chromatography in the isocratic elution mode. J Anal Chem. 2000;55:58-65. [Google Scholar]
71. Kurgan Önder C, Balcı N, et al. Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study. Clin Oral Investig. 2022;26:5721-5732. [DOI] [PubMed] [Google Scholar]
72. Leichtle AB, Nuoffer JM, Ceglarek U, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics. 2012;8:643-653. [DOI] [PMC free article] [PubMed] [Google Scholar]
73. Li Y, Tang AG, Mu S. HPLC–FLD determination of serum aromatic amino acids: application in chronic kidney disease patients. Clin Chim Acta. 2011;412: 1032-1035. [DOI] [PubMed] [Google Scholar]
74. Lim CK, Bilgin A, Lovejoy DB, et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep. 2017;7:41473. [DOI] [PMC free article] [PubMed] [Google Scholar]
75. Lionetto L, Ulivieri M, Capi M, et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: an observational cohort study. Biochim Biophys Acta. 2021;1867:166042. [DOI] [PMC free article] [PubMed] [Google Scholar]
76. Liu H, Ding L, Zhang H, et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front Psychiatry. 2018;9:552. [DOI] [PMC free article] [PubMed] [Google Scholar]
77. Torres MI, López-Casado MA, Lorite P, Ríos A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin Exp Immunol. 2007;148:419-424. [DOI] [PMC free article] [PubMed] [Google Scholar]
78. Lu Y, Wang Y, Liang X, et al. Serum amino acids in association with prevalent and incident type 2 diabetes in a Chinese population. Metabolites. 2019;9:14. [DOI] [PMC free article] [PubMed] [Google Scholar]
79. Ma L, Xu B, Wang W, Deng W, Ding M. Analysis of tryptophan catabolism in HBV patients by HPLC with programmed wavelength ultraviolet detection. Clin Chim Acta. 2009;405:94-96. [DOI] [PubMed] [Google Scholar]
80. Malhotra R, Persic V, Zhang W, et al. Tryptophan and kynurenine levels and its association with sleep, nonphysical fatigue, and depression in chronic hemodialysis patients. J Ren Nutr. 2017;27:260-266. [DOI] [PubMed] [Google Scholar]
81. Meng L, Shi H, Wang DG, et al. Specific metabolites involved in antioxidation and mitochondrial function are correlated with frailty in elderly men. Front Med. 2022;9. [DOI] [PMC free article] [PubMed] [Google Scholar]
82. Michel M, Salvador C, Wiedemair V, et al. Method comparison of HPLC-ninhydrin-photometry and UHPLC-PITC-tandem mass spectrometry for serum amino acid analyses in patients with complex congenital heart disease and controls. Metabolomics. 2020;16:128. [DOI] [PMC free article] [PubMed] [Google Scholar]
83. Mierzchala-Pasierb M, Lipinska-Gediga M, Fleszar MG, et al. Altered profiles of serum amino acids in patients with sepsis and septic shock - preliminary findings. Arch Biochem Biophys. 2020;691:108508. [DOI] [PubMed] [Google Scholar]
84. Mu S, Li Y, Tang A, Xiao L, Ren Y. Simultaneous determination of tyrosine, tryptophan and 5-hydroxytryptamine in serum of MDD patients by high performance liquid chromatography with fluorescence detection. Clin Chim Acta. 2012; 413:973-977. [DOI] [PubMed] [Google Scholar]
85. Myint AM, Kim YK, Verkerk R, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102:65-72. [DOI] [PubMed] [Google Scholar]
86. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143-151. [DOI] [PubMed] [Google Scholar]
87. Nakatsukasa M, Sotozono C, Shimbo K, et al. Amino acid profiles in human tear fluids analyzed by high-performance liquid chromatography and electrospray ionization tandem mass spectrometry. Am J Ophthalmol. 2011; 151:799-808.e1. [DOI] [PubMed] [Google Scholar]
88. Naz S, Bhat M, Ståhl S, et al. Dysregulation of the tryptophan pathway evidences gender differences in COPD. Metabolites. 2019;9:212. [DOI] [PMC free article] [PubMed] [Google Scholar]
89. Ogawa S, Koga N, Hattori K, et al. Plasma amino acid profile in major depressive disorder: analyses in two independent case-control sample sets. J Psychiatr Res. 2018;96:23-32. [DOI] [PubMed] [Google Scholar]
90. Oh JS, Seo HS, Kim KH, et al. Urinary profiling of tryptophan and its related metabolites in patients with metabolic syndrome by liquid chromatography-electrospray ionization/mass spectrometry. Anal Bioanal Chem. 2017;409: 5501-5512. [DOI] [PubMed] [Google Scholar]
91. Ohashi H, Iizuka H, Yoshihara S, et al. Determination of l-tryptophan and l-kynurenine in human serum by using LC-MS after derivatization with (R)-DBD-PyNCS. Int J Tryptophan Res. 2013;6:9-14. [DOI] [PMC free article] [PubMed] [Google Scholar]
92. Onesti CE, Boemer F, Josse C, et al. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. J Transl Med. 2019;17:239. [DOI] [PMC free article] [PubMed] [Google Scholar]
93. Palabiyik SS, Keles S, Girgin G, et al. Neopterin release and tryptophan degradation in patients with uveitis. Curr Eye Res. 2016;41:1513-1517. [DOI] [PubMed] [Google Scholar]
94. Panitz V, Končarević S, Sadik A, et al. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics. 2021; 11:9217-9233. [DOI] [PMC free article] [PubMed] [Google Scholar]
95. Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren’s syndrome. Clin Exp Immunol. 2005;142:155-161. [DOI] [PMC free article] [PubMed] [Google Scholar]
96. Primiano A, Persichilli S, Ferraro PM, et al. A specific urinary amino acid profile characterizes people with kidney stones. Dis Markers. 2020;2020:8848225. [DOI] [PMC free article] [PubMed] [Google Scholar]
97. Ren YP, Tang AG, Zhou QX, Xiang ZY. Clinical significance of simultaneous determination of serum tryptophan and tyrosine in patients with lung cancer. J Clin Lab Anal. 2011;25:246-250. [DOI] [PMC free article] [PubMed] [Google Scholar]
98. Roca P, Proenza AM, Palou A. Sex differences in the effect of obesity on human plasma tryptophan/large neutral amino acid ratio. Ann Nutr Metab. 1999;43: 145-151. [DOI] [PubMed] [Google Scholar]
99. Rodrigues FB, Byrne LM, Lowe AJ, et al. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s disease. J Neurochem. 2021;158:539-553. [DOI] [PMC free article] [PubMed] [Google Scholar]
100. Ruoppolo M, Campesi I, Scolamiero E, et al. Serum metabolomic profiles suggest influence of sex and oral contraceptive use. Am J Transl Res. 2014;6: 614-624. [PMC free article] [PubMed] [Google Scholar]
101. Saito A, Maeda K, Kobayashi K, et al. An automated technique for the analysis of serum indolic tryptophan metabolites and their accumulation in uremia. Jpn J Clin Chem. 1979;8:198-203. [Google Scholar]
102. Saito K, Ishikawa R, Kitamura I, et al. Characterization of serotonin as a candidate biomarker of severity and prognosis of COVID-19 using LC/MS analysis. J Pharmacol Sci. 2022;150:49-55. [DOI] [PMC free article] [PubMed] [Google Scholar]
103. Sakaguchi Y, Yoshida H, Hayama T, et al. Selective liquid-chromatographic determination of native fluorescent biogenic amines in human urine based on fluorous derivatization. J Chromatogr A. 2011;1218:5581-5586. [DOI] [PubMed] [Google Scholar]
104. Schwieler L, Trepci A, Krzyzanowski S, et al. A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid. Bioanalysis. 2020;12:379-392. [DOI] [PMC free article] [PubMed] [Google Scholar]
105. Shi W, Wu J, Tan Q, et al. Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients. Infect Drug Resist. 2019;12:1265-1276. [DOI] [PMC free article] [PubMed] [Google Scholar]
106. Smolenska Z, Zabielska-Kaczorowska M, Wojteczek A, Kutryb-Zajac B, Zdrojewski Z. Metabolic pattern of systemic sclerosis: association of changes in plasma concentrations of amino acid-related compounds with disease presentation. Front Mol Biosci. 2020;7. [DOI] [PMC free article] [PubMed] [Google Scholar]
107. Sorgdrager FJH, Doornbos B, Penninx BWJH, de Jonge P, Kema IP. The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls. J Affect Disord. 2017;222:32-39. [DOI] [PubMed] [Google Scholar]
108. Sorgdrager FJH, Vermeiren Y, Van Faassen M, et al. Age- and disease-specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease. J Neurochem. 2019;151:656-668. [DOI] [PMC free article] [PubMed] [Google Scholar]
109. Souissi S, Ghedira R, Macherki Y, et al. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival. Immun Inflamm Dis. 2022;10:e690. [DOI] [PMC free article] [PubMed] [Google Scholar]
110. Sousa A, Ribeiro C, Gonçalves VMF, et al. Development and validation of a liquid chromatography method using UV/fluorescence detection for the quantitative determination of metabolites of the kynurenine pathway in human urine: application to patients with heart failure. J Pharm Biomed Anal. 2021; 198:113997. [DOI] [PubMed] [Google Scholar]
111. Sultana N, Arayne MS, Khan MM, Saleem DM, Mirza AZ. Determination of tryptophan in raw materials, rat brain and human plasma by RP-HPLC technique. J Chromatogr Sci. 2012;50:531-537. [DOI] [PubMed] [Google Scholar]
112. Sun S, He D, Luo C, et al. Metabolic syndrome and its components are associated with altered amino acid profile in Chinese Han population. Front Endocrinol. 2021;12:795044. [DOI] [PMC free article] [PubMed] [Google Scholar]
113. Sun XZ, Zhao DY, Zhou YC, et al. Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer. World J Gastroenterol. 2020;26:7173-7190. [DOI] [PMC free article] [PubMed] [Google Scholar]
114. Suzuki Y, Suda T, Asada K, et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin Vaccine Immunol. 2012;19: 436-442. [DOI] [PMC free article] [PubMed] [Google Scholar]
115. Suzuki Y, Suda T, Furuhashi K, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67: 361-365. [DOI] [PubMed] [Google Scholar]
116. Suzuki Y, Suda T, Yokomura K, et al. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. J Infect. 2011; 63:215-222. [DOI] [PubMed] [Google Scholar]
117. Taherizadeh M, Khoshnia M, Shams S, Hesari Z, Joshaghani H. Clinical significance of plasma levels of gluconeogenic amino acids in esophageal cancer patients. Asian Pac J Cancer Prev. 2020;21:2463-2468. [DOI] [PMC free article] [PubMed] [Google Scholar]
118. Tcherkas YV, Kartsova LA, Krasnova IN. Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr A. 2001;913:303-308. [DOI] [PubMed] [Google Scholar]
119. Tezcan D, Onmaz DE, Sivrikaya A, et al. Kynurenine pathway of tryptophan metabolism in patients with familial Mediterranean fever. Mod Rheumatol. 2023;33:398-407. [DOI] [PubMed] [Google Scholar]
120. Tong Q, Song J, Yang G, et al. Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. 2018;32. [DOI] [PubMed] [Google Scholar]
121. Trepci A, Sellgren CM, Pålsson E, et al. Central levels of tryptophan metabolites in subjects with bipolar disorder. Eur Neuropsychopharmacol. 2021;43: 52-62. [DOI] [PubMed] [Google Scholar]
122. Tuka B, Nyári A, Cseh EK, et al. Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period. J Headache Pain. 2021;22:60. [DOI] [PMC free article] [PubMed] [Google Scholar]
123. Uchikura K. Determination of aromatic and branched-chain amino acids in plasma by HPLC with electrogenerated Ru(bpy)33+ chemiluminescence detection. Chem Pharm Bull. 2003;51:1092-1094. [DOI] [PubMed] [Google Scholar]
124. Valko-Rokytovská M, Hubková B, Birková A, et al. Specific urinary metabolites in malignant melanoma. Medicinar. 2019;55. [DOI] [PMC free article] [PubMed] [Google Scholar]
125. van Faassen M, Bouma G, de Hosson LD, et al. Quantitative profiling of platelet-rich plasma indole markers by direct-matrix derivatization combined with LC-MS/MS in patients with neuroendocrine tumors. Clin Chem. 2019; 65:1388-1396. [DOI] [PubMed] [Google Scholar]
126. Walser M, Hill SB. Free and protein-bound tryptophan in serum of untreated patients with chronic renal failure. Kidney Int. 1993;44:1366-1371. [DOI] [PubMed] [Google Scholar]
127. Wang FH, Liu J, Deng QJ, et al. Association between plasma essential amino acids and atherogenic lipid profile in a Chinese population: a cross-sectional study. Atherosclerosis. 2019;286:7-13. [DOI] [PubMed] [Google Scholar]
128. Wang SM, Yang RY, Wang M, et al. Identification of serum metabolites associated with obesity and traditional risk factors for metabolic disease in Chinese adults. Nutr Metab Cardiovasc Dis. 2018;28:112-118. [DOI] [PubMed] [Google Scholar]
129. Widner B, Leblhuber F, Walli J, et al. Tryptophan degradation and immune activation in Alzheimer’s disease. J Neural Transm. 2000;107:343-353. [DOI] [PubMed] [Google Scholar]
130. Wu D, Chen M, Chen S, et al. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis. Clin Rheumatol. 2022;41:3107-3117. [DOI] [PMC free article] [PubMed] [Google Scholar]
131. Wu Y, Mai N, Weng X, Liang J, Ning Y. Changes of altruistic behavior and kynurenine pathway in late-life depression. Front Psychiatry. 2020;11:338. [DOI] [PMC free article] [PubMed] [Google Scholar]
132. Wu Y, Zhong X, Mai N, et al. Kynurenine pathway changes in late-life depression. J Affect Disord. 2018;235:76-81. [DOI] [PubMed] [Google Scholar]
133. Xu HB, Fang L, Hu ZC, et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 2012;200: 1054-1057. [DOI] [PubMed] [Google Scholar]
134. Yan J, Kuzhiumparambil U, Bandodkar S, Solowij N, Fu S. Development and validation of a simple, rapid and sensitive LC-MS/MS method for the measurement of urinary neurotransmitters and their metabolites. Anal Bioanal Chem. 2017;409:7191-7199. [DOI] [PubMed] [Google Scholar]
135. Yao JK, Dougherty Gg, Jr, Reddy RD, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010;15:938-953. [DOI] [PMC free article] [PubMed] [Google Scholar]
136. Yilmaz A, Ugur Z, Bisgin H, et al. Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer’s disease and mild cognitive impairment: a pilot study. Metabolites. 2020;10:357. [DOI] [PMC free article] [PubMed] [Google Scholar]
137. Yoshitake M, Nohta H, Ogata S, et al. Liquid chromatography method for detecting native fluorescent bioamines in urine using post-column derivatization and intramolecular FRET detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:307-312. [DOI] [PubMed] [Google Scholar]
138. Zhang Z, Zhang M, Luo Y, et al. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls. Hum Psychopharmacol. 2020;35:e2738. [DOI] [PubMed] [Google Scholar]
139. Zhao J, Chen H, Ni P, et al. Simultaneous determination of urinary tryptophan, tryptophan-related metabolites and creatinine by high performance liquid chromatography with ultraviolet and fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:2720-2725. [DOI] [PubMed] [Google Scholar]
140. Zhen Q, Xu B, Ma L, et al. Simultaneous determination of tryptophan, kynurenine and 5-hydroxytryptamine by HPLC: application in uremic patients undergoing hemodialysis. Clin Biochem. 2011;44:226-230. [DOI] [PubMed] [Google Scholar]
141. Zhou S, Huang Y, Kuang Q, et al. Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia. Front Psychiatry. 2022;13. [DOI] [PMC free article] [PubMed] [Google Scholar]
142. Zhou Y, Zheng W, Liu W, et al. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. Psychoneuroendocrinology. 2019;101:72-79. [DOI] [PubMed] [Google Scholar]
143. Hampel H, O’Bryant SE, Durrleman S, et al.; for the Alzheimer Precision Medicine Initiative. A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric. 2017; 20:107-118. [DOI] [PubMed] [Google Scholar]
144. Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med. 2016;4:107. [DOI] [PMC free article] [PubMed] [Google Scholar]
145. Züllig T, Köfeler HC. High resolution mass spectrometry in lipidomics. Mass Spectrom Rev. 2021;40:162-176. [DOI] [PMC free article] [PubMed] [Google Scholar]
146. Chen C, Hou J, Tanner JJ, Cheng J. Bioinformatics methods for mass spectrometry-based proteomics data analysis. Int J Mol Sci. 2020;21:2873. [DOI] [PMC free article] [PubMed] [Google Scholar]
147. Jove M, Spencer J, Clench M, Loadman PM, Twelves C. Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol. 2019;141:153-162. [DOI] [PubMed] [Google Scholar]
148. Churchwell MI, Twaddle NC, Meeker LR, Doerge DR. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to hplc-es/ms/ms.-ES. J Chromatogr B. 2005;825: 134-143. [DOI] [PubMed] [Google Scholar]
149. Slavík J. Absorption spectroscopy. Intracellular pH and Its Measurement. 1989:69. [Google Scholar]
150. Fukunaga Y, Katsuragi Y, Izumi T, Sakiyama F. Fluorescence characteristics of kynurenine and N′-formylkynurenine, their use as reporters of the environment of tryptophan 62 in hen egg-white lysozyme1. J Biochem. 1982;92:129-141. [DOI] [PubMed] [Google Scholar]
151. Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacol. 2017;112:248-263. [DOI] [PubMed] [Google Scholar]
152. Ninomiya S, Nakamura N, Nakamura H, et al. Low levels of serum tryptophan underlie skeletal muscle atrophy. Nutrients. 2020;12:978. [DOI] [PMC free article] [PubMed] [Google Scholar]
153. Murr C, Grammer TB, Kleber ME, et al. Low serum tryptophan predicts higher mortality in cardiovascular disease. Eur J Clin Invest. 2015;45:247-254. [DOI] [PubMed] [Google Scholar]
154. Zhang A, Sun H, Wang X. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl Biochem Biotechnol. 2012;168:1718-1727. [DOI] [PubMed] [Google Scholar]
155. Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev. 2017;36: 115-134. [DOI] [PubMed] [Google Scholar]
156. Miller RC, Brindle E, Holman DJ, et al. Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations. Clin Chem. 2004;50:924-932. [DOI] [PubMed] [Google Scholar]
157. Ağagündüz D, Kocaadam-Bozkurt B, Bozkurt O, et al. Microbiota alteration and modulation in Alzheimer’s disease by gerobiotics: the gut-health axis for a good mind. Biomed Pharmacother. 2022;153. [DOI] [PubMed] [Google Scholar]
158. Jacobs KR, Lim CK, Blennow K, et al. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer’s disease and relationship to amyloid-β and tau. Neurobiol Aging. 2019;80:11-20. [DOI] [PubMed] [Google Scholar]
159. Székely G, Henriques B, Gil M, Alvarez C. Experimental design for the optimization and robustness testing of a liquid chromatography tandem mass spectrometry method for the trace analysis of the potentially genotoxic 1,3-diisopropylurea. Drug Test Anal. 2014;6:898-908. [DOI] [PubMed] [Google Scholar]
160. Chaleckis R, Meister I, Zhang P, Wheelock CE. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. Curr Opin Biotechnol. 2019;55:44-50. [DOI] [PubMed] [Google Scholar]
161. Solvang SH, Hodge A, Watne LO, et al. Kynurenine pathway metabolites in the blood and cerebrospinal fluid are associated with human aging. Oxid Med Cell Longev. 2022;2022:5019752. [DOI] [PMC free article] [PubMed] [Google Scholar]
162. Lassen JK, Wang T, Nielsen KL, et al. Large-scale metabolomics: predicting biological age using 10,133 routine untargeted LC-MS measurements. Aging Cell. 2023;22:e13813. [DOI] [PMC free article] [PubMed] [Google Scholar]
163. Guo L, Zhong MB, Zhang L, Zhang B, Cai D. Sex differences in Alzheimer’s disease: Insights from the multiomics landscape. Biol Psychiatry. 2022;91:61-71. [DOI] [PMC free article] [PubMed] [Google Scholar]
164. Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D. Role of kynurenine pathway in oxidative stress during neurodegenerative disorders. Cells. 2021;10:1603. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file.^{(85.5KB, docx)}

Click here for additional data file.^{(31.5KB, docx)}

[bibr1-11786469231211184] 1. Marx W, McGuinness AJ, Rocks T, et al. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. Mol Psychiatry. 2021;26:4158-4178. [DOI] [PubMed] [Google Scholar]

[bibr2-11786469231211184] 2. Qi Q, Li J, Yu B, et al. Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies. Gut. 2022;71:1095-1105. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr3-11786469231211184] 3. Maddison DC, Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol. 2015;40:134-141. [DOI] [PubMed] [Google Scholar]

[bibr4-11786469231211184] 4. Krupa A, Kowalska I. The kynurenine pathway-new linkage between innate and adaptive immunity in autoimmune endocrinopathies. Int J Mol Sci. 2021;22:9879. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr5-11786469231211184] 5. Zhang D, Ning J, Ramprasath T, et al. Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis. Nat Commun. 2022;13:6371. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]

[bibr6-11786469231211184] 6. Nguyen DT, Kleczko EK, Dwivedi N, et al. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight. 2023;8:e154773. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr7-11786469231211184] 7. Sofia MA, Ciorba MA, Meckel K, et al. Tryptophan metabolism through the kynurenine pathway is associated with endoscopic inflammation in ulcerative colitis. Inflamm Bowel Dis. 2018;24:1471-1480. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr8-11786469231211184] 8. Ala M. The footprint of kynurenine pathway in every cancer: a new target for chemotherapy. Eur J Pharmacol. 2021;896. [DOI] [PubMed] [Google Scholar]

[bibr9-11786469231211184] 9. Gao J, Xu K, Liu H, et al. Impact of the gut microbiota on intestinal immunity mediated by tryptophan metabolism. Front Cell Infect Microbiol. 2018;8:13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr10-11786469231211184] 10. Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364:82-90. [DOI] [PubMed] [Google Scholar]

[bibr11-11786469231211184] 11. Beger RD, Dunn W, Schmidt MA, et al.; for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. Metabolomics. 2016;12:149-215. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr12-11786469231211184] 12. Ogyu K, Kubo K, Noda Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018;90:16-25. [DOI] [PubMed] [Google Scholar]

[bibr13-11786469231211184] 13. Almulla AF, Vasupanrajit A, Tunvirachaisakul C, et al. The tryptophan catabolite or kynurenine pathway in schizophrenia: meta-analysis reveals dissociations between central, serum, and plasma compartments. Mol Psychiatry. 2022;27: 3679-3691. [DOI] [PubMed] [Google Scholar]

[bibr14-11786469231211184] 14. Cao B, Chen Y, Ren Z, et al. Dysregulation of kynurenine pathway and potential dynamic changes of kynurenine in schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;123:203-214. [DOI] [PubMed] [Google Scholar]

[bibr15-11786469231211184] 15. Hunt C, Macedo E, Cordeiro T, Suchting R, et al. Effect of immune activation on the kynurenine pathway and depression symptoms – a systematic review and meta-analysis. Neurosci Biobehav Rev. 2020;118:514-523. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr16-11786469231211184] 16. Lau CE, Siskos AP, Maitre L, et al. Determinants of the urinary and serum metabolome in children from six European populations. BMC Med. 2018;16: 202-219. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr17-11786469231211184] 17. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr18-11786469231211184] 18. Haider SI. Validation Standard Operating Procedures: A Step by Step Guide for Achieving Compliance in the Pharmaceutical, Medical Device, and Biotech Industries. CRC Press; 2006. [Google Scholar]

[bibr19-11786469231211184] 19. Lumbreras B, Porta M, Márquez S, et al. QUADOMICS: an adaptation of the Quality Assessment of Diagnostic Accuracy Assessment (QUADAS) for the evaluation of the methodological quality of studies on the diagnostic accuracy of ‘-omics’-based technologies. Clin Biochem. 2008;41:1316-1325. [DOI] [PubMed] [Google Scholar]

[bibr20-11786469231211184] 20. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 2003;3:25-13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr21-11786469231211184] 21. Joanna Briggs Institute. The Joanna Briggs Institute Critical Appraisal Tools for Use in JBI Systematic Reviews Checklist for Analytical Cross Sectional Studies. North Adelaide, Australia The Joanna Briggs Institute; 2017. [Google Scholar]

[bibr22-11786469231211184] 22. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr23-11786469231211184] 23. Adrych K, Smoczynski M, Stojek M, et al. Decreased serum essential and aromatic amino acids in patients with chronic pancreatitis. World J Gastroenterol. 2010;16:4422-4427. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr24-11786469231211184] 24. Al Saedi A, Chow S, Vogrin S, Guillemin GJ, Duque G. Association between tryptophan metabolites, physical performance, and frailty in older persons. Int J Tryptophan Res. 2022;15. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr25-11786469231211184] 25. Arnhard K, Pitterl F, Sperner-Unterweger B, et al. A validated liquid chromatography-high resolution-tandem mass spectrometry method for the simultaneous quantitation of tryptophan, kynurenine, kynurenic acid, and quinolinic acid in human plasma. Electrophoresis. 2018;39:1171-1180. [DOI] [PubMed] [Google Scholar]

[bibr26-11786469231211184] 26. Bai JH, Zheng YL, Yu YP. Urinary kynurenine as a biomarker for Parkinson’s disease. Neurol Sci. 2021;42:697-703. [DOI] [PubMed] [Google Scholar]

[bibr27-11786469231211184] 27. Barry S, Clarke G, Scully P, Dinan TG. Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. J Psychopharmacol. 2009;23:287-294. [DOI] [PubMed] [Google Scholar]

[bibr28-11786469231211184] 28. Bassi R, Niewczas MA, Biancone L, et al. Metabolomic profiling in individuals with a failing kidney allograft. PLoS One. 2017;12:e0169077. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr29-11786469231211184] 29. Bizzarri M, Catizone A, Pompei M, et al. Determination of urinary tryptophan and its metabolites along the nicotinic acid pathway by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr. 1990;4:24-27. [DOI] [PubMed] [Google Scholar]

[bibr30-11786469231211184] 30. Buczko P, Tankiewicz-Kwedlo A, Buraczewska A, Pawlak D, Mysliwiec M. Accumulation of kynurenine pathway metabolites in salive and plasma of uremic patients. Pharmacol Rep. 2007;59:199-204.17556798 [Google Scholar]

[bibr31-11786469231211184] 31. Calvani R, Rodriguez-Mañas L, Picca A, et al. Identification of a circulating amino acid signature in frail older persons with type 2 diabetes mellitus: results from the metabofrail study. Nutrients. 2020;12:199. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr32-11786469231211184] 32. Capuron L, Schroecksnadel S, Féart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry. 2011;70:175-182. [DOI] [PubMed] [Google Scholar]

[bibr33-11786469231211184] 33. Chang KH, Cheng ML, Tang HY, et al. Alternations of metabolic profile and kynurenine metabolism in the plasma of Parkinson’s disease. Mol Neurobiol. 2018;55:6319-6328. [DOI] [PubMed] [Google Scholar]

[bibr34-11786469231211184] 34. Chatterjee P, Zetterberg H, Goozee K, et al. Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease. J Neuroinflammation. 2019;16:186. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr35-11786469231211184] 35. Chen Y, Chen H, Shi G, et al. Ultra-performance liquid chromatography-tandem mass spectrometry quantitative profiling of tryptophan metabolites in human plasma and its application to clinical study. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1128. [DOI] [PubMed] [Google Scholar]

[bibr36-11786469231211184] 36. Chen Y, Stankovic R, Cullen KM, et al. The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res. 2010;18:132-142. [DOI] [PubMed] [Google Scholar]

[bibr37-11786469231211184] 37. Chen Z, Lin F, Ye X, et al. Simultaneous determination of five essential amino acids in plasma of hyperlipidemic subjects by UPLC-MS/MS. Lipids Health Dis. 2020;19:52. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr38-11786469231211184] 38. Cheng F, Wang Z, Huang Y, Duan Y, Wang X. Investigation of salivary free amino acid profile for early diagnosis of breast cancer with ultra performance liquid chromatography-mass spectrometry. Clin Chim Acta. 2015;447:23-31. [DOI] [PubMed] [Google Scholar]

[bibr39-11786469231211184] 39. Clarke G, Fitzgerald P, Cryan JF, et al. Tryptophan degradation in irritable bowel syndrome: evidence of indoleamine 2,3-dioxygenase activation in a male cohort. BMC Gastroenterol. 2009;9:6. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr40-11786469231211184] 40. Colle R, Masson P, Verstuyft C, et al. Peripheral tryptophan, serotonin, kynurenine, and their metabolites in major depression: a case-control study. Psychiatry Clin Neurosci. 2020;74:112-117. [DOI] [PubMed] [Google Scholar]

[bibr41-11786469231211184] 41. Crotti S, Bedin C, Bertazzo A, et al. Tryptophan metabolism as source of new prognostic biomarkers for FAP patients. Int J Tryptophan Res. 2019;12. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr42-11786469231211184] 42. Cseh EK, Veres G, Szentirmai M, et al. HPLC method for the assessment of tryptophan metabolism utilizing separate internal standard for each detector. Anal Biochem. 2019;574:7-14. [DOI] [PubMed] [Google Scholar]

[bibr43-11786469231211184] 43. Curto M, Lionetto L, Negro A, et al. Altered kynurenine pathway metabolites in serum of chronic migraine patients. J Headache Pain. 2015;17:47. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr44-11786469231211184] 44. Curto M, Lionetto L, Negro A, et al. Altered serum levels of kynurenine metabolites in patients affected by cluster headache. J Headache Pain. 2015;17:27. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr45-11786469231211184] 45. Domingues DS, Crevelin EJ, de Moraes LA, et al. Simultaneous determination of amino acids and neurotransmitters in plasma samples from schizophrenic patients by hydrophilic interaction liquid chromatography with tandem mass spectrometry. J Sep Sci. 2015;38:780-787. [DOI] [PubMed] [Google Scholar]

[bibr46-11786469231211184] 46. Doolin K, Allers KA, Pleiner S, et al. Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology. 2018;95:8-17. [DOI] [PubMed] [Google Scholar]

[bibr47-11786469231211184] 47. Eniu DT, Romanciuc F, Moraru C, et al. The decrease of some serum free amino acids can predict breast cancer diagnosis and progression. Scand J Clin Lab Invest. 2019;79:17-24. [DOI] [PubMed] [Google Scholar]

[bibr48-11786469231211184] 48. Fekkes D, van der Cammen TJ, van Loon CP, et al. Abnormal amino acid metabolism in patients with early stage Alzheimer dementia. J Neural Transm. 1998;105:287-294. [DOI] [PubMed] [Google Scholar]

[bibr49-11786469231211184] 49. Fitzgerald P, Cassidy Eugene M, Clarke G, et al. Tryptophan catabolism in females with irritable bowel syndrome: relationship to interferon-gamma, severity of symptoms and psychiatric co-morbidity. Neurogastroenterol Motil. 2008;20: 1291-1297. [DOI] [PubMed] [Google Scholar]

[bibr50-11786469231211184] 50. Frick B, Schroecksnadel K, Neurauter G, Leblhuber F, Fuchs D. Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. Clin Biochem. 2004;37:684-687. [DOI] [PubMed] [Google Scholar]

[bibr51-11786469231211184] 51. Fukushima T, Iizuka H, Yokota A, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum d-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014;9:e101652. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr52-11786469231211184] 52. Furtado DZS, de Moura Leite FBV, Barreto CN, et al. Profiles of amino acids and biogenic amines in the plasma of Cri-du-Chat patients. J Pharm Biomed Anal. 2017;140:137-145. [DOI] [PubMed] [Google Scholar]

[bibr53-11786469231211184] 53. Galla Z, Rácz G, Grecsó N, et al. Improved LC-MS/MS method for the determination of 42 neurologically and metabolically important molecules in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1179. [DOI] [PubMed] [Google Scholar]

[bibr54-11786469231211184] 54. Geisler S, Mayersbach P, Becker K, et al. Serum tryptophan, kynurenine, phenylalanine, tyrosine and neopterin concentrations in 100 healthy blood donors. Pteridines. 2015;26:31-36. [Google Scholar]

[bibr55-11786469231211184] 55. Rosas HD, Doros G, Bhasin S, et al. A systems-level “misunderstanding”: the plasma metabolome in Huntington’s disease. Ann Clin Transl Neurol. 2015;2: 756-768. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr56-11786469231211184] 56. Gürcü S, Girgin G, Yorulmaz G, et al. Neopterin and biopterin levels and tryptophan degradation in patients with diabetes. Sci Rep. 2020;10:17025. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr57-11786469231211184] 57. Gomez-Gomez A, Marcos J, Aguilera P, To-Figueras J, Pozo OJ. Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1060:347-354. [DOI] [PubMed] [Google Scholar]

[bibr58-11786469231211184] 58. Gulaj E, Pawlak K, Bien B, Pawlak D. Kynurenine and its metabolites in Alzheimer’s disease patients. Adv Med Sci. 2010;55:204-211. [DOI] [PubMed] [Google Scholar]

[bibr59-11786469231211184] 59. Hajsl M, Hlavackova A, Broulikova K, et al. Tryptophan metabolism, inflammation, and oxidative stress in patients with neurovascular disease. Metabolites. 2020;10. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr60-11786469231211184] 60. Han M, Xie M, Han J, et al. Development and validation of a rapid, selective, and sensitive LC–MS/MS method for simultaneous determination of d- and l-amino acids in human serum: application to the study of hepatocellular carcinoma. Anal Bioanal Chem. 2018;410:2517-2531. [DOI] [PubMed] [Google Scholar]

[bibr61-11786469231211184] 61. Hényková E, Vránová HP, Amakorová P, et al. Stable isotope dilution ultra-high performance liquid chromatography-tandem mass spectrometry quantitative profiling of tryptophan-related neuroactive substances in human serum and cerebrospinal fluid. J Chromatogr A. 2016;1437:145-157. [DOI] [PubMed] [Google Scholar]

[bibr62-11786469231211184] 62. Huang J, Zhang P, Zhou Y, et al. Serum kynurenine metabolites might not be associated with risk factors of treatment-resistant schizophrenia. J Psychiatr Res. 2022;145:339-346. [DOI] [PubMed] [Google Scholar]

[bibr63-11786469231211184] 63. Huang R, Shen K, He Q, et al. Metabolic profiling of urinary chiral amino-containing biomarkers for gastric cancer using a sensitive chiral chlorine-labeled probe by HPLC-MS/MS. J Proteome Res. 2021;20:3952-3962. [DOI] [PubMed] [Google Scholar]

[bibr64-11786469231211184] 64. Islam MR, Ali S, Karmoker JR, et al. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020;20:333. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr65-11786469231211184] 65. Jang JH, Yoo SY, Park YE, et al. The kynurenine pathway and mediating role of stress in addictive disorders: A focus on alcohol use disorder and internet gaming disorder. Front Pharmacol. 2022;13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr66-11786469231211184] 66. Kim HJ, Jang SH, Ryu JS, et al. The performance of a novel amino acid multivariate index for detecting lung cancer: a case control study in Korea. Lung Cancer. 2015;90:522-527. [DOI] [PubMed] [Google Scholar]

[bibr67-11786469231211184] 67. Kim YK, Myint AM, Verkerk R, et al. Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. Neuropsychobiology. 2009;59:123-129. [DOI] [PubMed] [Google Scholar]

[bibr68-11786469231211184] 68. Klatt S, Doecke JD, Roberts A, et al. A six-metabolite panel as potential blood-based biomarkers for Parkinson’s disease. Parkinsons Dis. 2021;7:94. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr69-11786469231211184] 69. Koch DD, Kissinger PT. Determination of tryptophan and several of its metabolites in physiological samples by reversed-phase liquid chromatography with electrochemical detection. J Chromatogr. 1979;164:444-455. [PubMed] [Google Scholar]

[bibr70-11786469231211184] 70. Krasnova IN, Kartsova LA, Cherkas YV. Determination of amino acids in human blood serum by reversed-phase high-performance liquid chromatography in the isocratic elution mode. J Anal Chem. 2000;55:58-65. [Google Scholar]

[bibr71-11786469231211184] 71. Kurgan Önder C, Balcı N, et al. Influence of periodontal inflammation on tryptophan-kynurenine metabolism: a cross-sectional study. Clin Oral Investig. 2022;26:5721-5732. [DOI] [PubMed] [Google Scholar]

[bibr72-11786469231211184] 72. Leichtle AB, Nuoffer JM, Ceglarek U, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics. 2012;8:643-653. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr73-11786469231211184] 73. Li Y, Tang AG, Mu S. HPLC–FLD determination of serum aromatic amino acids: application in chronic kidney disease patients. Clin Chim Acta. 2011;412: 1032-1035. [DOI] [PubMed] [Google Scholar]

[bibr74-11786469231211184] 74. Lim CK, Bilgin A, Lovejoy DB, et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep. 2017;7:41473. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr75-11786469231211184] 75. Lionetto L, Ulivieri M, Capi M, et al. Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: an observational cohort study. Biochim Biophys Acta. 2021;1867:166042. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr76-11786469231211184] 76. Liu H, Ding L, Zhang H, et al. The metabolic factor kynurenic acid of kynurenine pathway predicts major depressive disorder. Front Psychiatry. 2018;9:552. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr77-11786469231211184] 77. Torres MI, López-Casado MA, Lorite P, Ríos A. Tryptophan metabolism and indoleamine 2,3-dioxygenase expression in coeliac disease. Clin Exp Immunol. 2007;148:419-424. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr78-11786469231211184] 78. Lu Y, Wang Y, Liang X, et al. Serum amino acids in association with prevalent and incident type 2 diabetes in a Chinese population. Metabolites. 2019;9:14. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr79-11786469231211184] 79. Ma L, Xu B, Wang W, Deng W, Ding M. Analysis of tryptophan catabolism in HBV patients by HPLC with programmed wavelength ultraviolet detection. Clin Chim Acta. 2009;405:94-96. [DOI] [PubMed] [Google Scholar]

[bibr80-11786469231211184] 80. Malhotra R, Persic V, Zhang W, et al. Tryptophan and kynurenine levels and its association with sleep, nonphysical fatigue, and depression in chronic hemodialysis patients. J Ren Nutr. 2017;27:260-266. [DOI] [PubMed] [Google Scholar]

[bibr81-11786469231211184] 81. Meng L, Shi H, Wang DG, et al. Specific metabolites involved in antioxidation and mitochondrial function are correlated with frailty in elderly men. Front Med. 2022;9. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr82-11786469231211184] 82. Michel M, Salvador C, Wiedemair V, et al. Method comparison of HPLC-ninhydrin-photometry and UHPLC-PITC-tandem mass spectrometry for serum amino acid analyses in patients with complex congenital heart disease and controls. Metabolomics. 2020;16:128. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr83-11786469231211184] 83. Mierzchala-Pasierb M, Lipinska-Gediga M, Fleszar MG, et al. Altered profiles of serum amino acids in patients with sepsis and septic shock - preliminary findings. Arch Biochem Biophys. 2020;691:108508. [DOI] [PubMed] [Google Scholar]

[bibr84-11786469231211184] 84. Mu S, Li Y, Tang A, Xiao L, Ren Y. Simultaneous determination of tyrosine, tryptophan and 5-hydroxytryptamine in serum of MDD patients by high performance liquid chromatography with fluorescence detection. Clin Chim Acta. 2012; 413:973-977. [DOI] [PubMed] [Google Scholar]

[bibr85-11786469231211184] 85. Myint AM, Kim YK, Verkerk R, et al. Tryptophan breakdown pathway in bipolar mania. J Affect Disord. 2007;102:65-72. [DOI] [PubMed] [Google Scholar]

[bibr86-11786469231211184] 86. Myint AM, Kim YK, Verkerk R, et al. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98:143-151. [DOI] [PubMed] [Google Scholar]

[bibr87-11786469231211184] 87. Nakatsukasa M, Sotozono C, Shimbo K, et al. Amino acid profiles in human tear fluids analyzed by high-performance liquid chromatography and electrospray ionization tandem mass spectrometry. Am J Ophthalmol. 2011; 151:799-808.e1. [DOI] [PubMed] [Google Scholar]

[bibr88-11786469231211184] 88. Naz S, Bhat M, Ståhl S, et al. Dysregulation of the tryptophan pathway evidences gender differences in COPD. Metabolites. 2019;9:212. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr89-11786469231211184] 89. Ogawa S, Koga N, Hattori K, et al. Plasma amino acid profile in major depressive disorder: analyses in two independent case-control sample sets. J Psychiatr Res. 2018;96:23-32. [DOI] [PubMed] [Google Scholar]

[bibr90-11786469231211184] 90. Oh JS, Seo HS, Kim KH, et al. Urinary profiling of tryptophan and its related metabolites in patients with metabolic syndrome by liquid chromatography-electrospray ionization/mass spectrometry. Anal Bioanal Chem. 2017;409: 5501-5512. [DOI] [PubMed] [Google Scholar]

[bibr91-11786469231211184] 91. Ohashi H, Iizuka H, Yoshihara S, et al. Determination of l-tryptophan and l-kynurenine in human serum by using LC-MS after derivatization with (R)-DBD-PyNCS. Int J Tryptophan Res. 2013;6:9-14. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr92-11786469231211184] 92. Onesti CE, Boemer F, Josse C, et al. Tryptophan catabolism increases in breast cancer patients compared to healthy controls without affecting the cancer outcome or response to chemotherapy. J Transl Med. 2019;17:239. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr93-11786469231211184] 93. Palabiyik SS, Keles S, Girgin G, et al. Neopterin release and tryptophan degradation in patients with uveitis. Curr Eye Res. 2016;41:1513-1517. [DOI] [PubMed] [Google Scholar]

[bibr94-11786469231211184] 94. Panitz V, Končarević S, Sadik A, et al. Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. Theranostics. 2021; 11:9217-9233. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr95-11786469231211184] 95. Pertovaara M, Raitala A, Uusitalo H, et al. Mechanisms dependent on tryptophan catabolism regulate immune responses in primary Sjögren’s syndrome. Clin Exp Immunol. 2005;142:155-161. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr96-11786469231211184] 96. Primiano A, Persichilli S, Ferraro PM, et al. A specific urinary amino acid profile characterizes people with kidney stones. Dis Markers. 2020;2020:8848225. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr97-11786469231211184] 97. Ren YP, Tang AG, Zhou QX, Xiang ZY. Clinical significance of simultaneous determination of serum tryptophan and tyrosine in patients with lung cancer. J Clin Lab Anal. 2011;25:246-250. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr98-11786469231211184] 98. Roca P, Proenza AM, Palou A. Sex differences in the effect of obesity on human plasma tryptophan/large neutral amino acid ratio. Ann Nutr Metab. 1999;43: 145-151. [DOI] [PubMed] [Google Scholar]

[bibr99-11786469231211184] 99. Rodrigues FB, Byrne LM, Lowe AJ, et al. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s disease. J Neurochem. 2021;158:539-553. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr100-11786469231211184] 100. Ruoppolo M, Campesi I, Scolamiero E, et al. Serum metabolomic profiles suggest influence of sex and oral contraceptive use. Am J Transl Res. 2014;6: 614-624. [PMC free article] [PubMed] [Google Scholar]

[bibr101-11786469231211184] 101. Saito A, Maeda K, Kobayashi K, et al. An automated technique for the analysis of serum indolic tryptophan metabolites and their accumulation in uremia. Jpn J Clin Chem. 1979;8:198-203. [Google Scholar]

[bibr102-11786469231211184] 102. Saito K, Ishikawa R, Kitamura I, et al. Characterization of serotonin as a candidate biomarker of severity and prognosis of COVID-19 using LC/MS analysis. J Pharmacol Sci. 2022;150:49-55. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr103-11786469231211184] 103. Sakaguchi Y, Yoshida H, Hayama T, et al. Selective liquid-chromatographic determination of native fluorescent biogenic amines in human urine based on fluorous derivatization. J Chromatogr A. 2011;1218:5581-5586. [DOI] [PubMed] [Google Scholar]

[bibr104-11786469231211184] 104. Schwieler L, Trepci A, Krzyzanowski S, et al. A novel, robust method for quantification of multiple kynurenine pathway metabolites in the cerebrospinal fluid. Bioanalysis. 2020;12:379-392. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr105-11786469231211184] 105. Shi W, Wu J, Tan Q, et al. Plasma indoleamine 2,3-dioxygenase activity as a potential biomarker for early diagnosis of multidrug-resistant tuberculosis in tuberculosis patients. Infect Drug Resist. 2019;12:1265-1276. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr106-11786469231211184] 106. Smolenska Z, Zabielska-Kaczorowska M, Wojteczek A, Kutryb-Zajac B, Zdrojewski Z. Metabolic pattern of systemic sclerosis: association of changes in plasma concentrations of amino acid-related compounds with disease presentation. Front Mol Biosci. 2020;7. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr107-11786469231211184] 107. Sorgdrager FJH, Doornbos B, Penninx BWJH, de Jonge P, Kema IP. The association between the hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major depressive disorder and healthy controls. J Affect Disord. 2017;222:32-39. [DOI] [PubMed] [Google Scholar]

[bibr108-11786469231211184] 108. Sorgdrager FJH, Vermeiren Y, Van Faassen M, et al. Age- and disease-specific changes of the kynurenine pathway in Parkinson’s and Alzheimer’s disease. J Neurochem. 2019;151:656-668. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr109-11786469231211184] 109. Souissi S, Ghedira R, Macherki Y, et al. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival. Immun Inflamm Dis. 2022;10:e690. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr110-11786469231211184] 110. Sousa A, Ribeiro C, Gonçalves VMF, et al. Development and validation of a liquid chromatography method using UV/fluorescence detection for the quantitative determination of metabolites of the kynurenine pathway in human urine: application to patients with heart failure. J Pharm Biomed Anal. 2021; 198:113997. [DOI] [PubMed] [Google Scholar]

[bibr111-11786469231211184] 111. Sultana N, Arayne MS, Khan MM, Saleem DM, Mirza AZ. Determination of tryptophan in raw materials, rat brain and human plasma by RP-HPLC technique. J Chromatogr Sci. 2012;50:531-537. [DOI] [PubMed] [Google Scholar]

[bibr112-11786469231211184] 112. Sun S, He D, Luo C, et al. Metabolic syndrome and its components are associated with altered amino acid profile in Chinese Han population. Front Endocrinol. 2021;12:795044. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr113-11786469231211184] 113. Sun XZ, Zhao DY, Zhou YC, et al. Alteration of fecal tryptophan metabolism correlates with shifted microbiota and may be involved in pathogenesis of colorectal cancer. World J Gastroenterol. 2020;26:7173-7190. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr114-11786469231211184] 114. Suzuki Y, Suda T, Asada K, et al. Serum indoleamine 2,3-dioxygenase activity predicts prognosis of pulmonary tuberculosis. Clin Vaccine Immunol. 2012;19: 436-442. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr115-11786469231211184] 115. Suzuki Y, Suda T, Furuhashi K, et al. Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer. Lung Cancer. 2010;67: 361-365. [DOI] [PubMed] [Google Scholar]

[bibr116-11786469231211184] 116. Suzuki Y, Suda T, Yokomura K, et al. Serum activity of indoleamine 2,3-dioxygenase predicts prognosis of community-acquired pneumonia. J Infect. 2011; 63:215-222. [DOI] [PubMed] [Google Scholar]

[bibr117-11786469231211184] 117. Taherizadeh M, Khoshnia M, Shams S, Hesari Z, Joshaghani H. Clinical significance of plasma levels of gluconeogenic amino acids in esophageal cancer patients. Asian Pac J Cancer Prev. 2020;21:2463-2468. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr118-11786469231211184] 118. Tcherkas YV, Kartsova LA, Krasnova IN. Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr A. 2001;913:303-308. [DOI] [PubMed] [Google Scholar]

[bibr119-11786469231211184] 119. Tezcan D, Onmaz DE, Sivrikaya A, et al. Kynurenine pathway of tryptophan metabolism in patients with familial Mediterranean fever. Mod Rheumatol. 2023;33:398-407. [DOI] [PubMed] [Google Scholar]

[bibr120-11786469231211184] 120. Tong Q, Song J, Yang G, et al. Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. 2018;32. [DOI] [PubMed] [Google Scholar]

[bibr121-11786469231211184] 121. Trepci A, Sellgren CM, Pålsson E, et al. Central levels of tryptophan metabolites in subjects with bipolar disorder. Eur Neuropsychopharmacol. 2021;43: 52-62. [DOI] [PubMed] [Google Scholar]

[bibr122-11786469231211184] 122. Tuka B, Nyári A, Cseh EK, et al. Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period. J Headache Pain. 2021;22:60. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr123-11786469231211184] 123. Uchikura K. Determination of aromatic and branched-chain amino acids in plasma by HPLC with electrogenerated Ru(bpy)33+ chemiluminescence detection. Chem Pharm Bull. 2003;51:1092-1094. [DOI] [PubMed] [Google Scholar]

[bibr124-11786469231211184] 124. Valko-Rokytovská M, Hubková B, Birková A, et al. Specific urinary metabolites in malignant melanoma. Medicinar. 2019;55. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr125-11786469231211184] 125. van Faassen M, Bouma G, de Hosson LD, et al. Quantitative profiling of platelet-rich plasma indole markers by direct-matrix derivatization combined with LC-MS/MS in patients with neuroendocrine tumors. Clin Chem. 2019; 65:1388-1396. [DOI] [PubMed] [Google Scholar]

[bibr126-11786469231211184] 126. Walser M, Hill SB. Free and protein-bound tryptophan in serum of untreated patients with chronic renal failure. Kidney Int. 1993;44:1366-1371. [DOI] [PubMed] [Google Scholar]

[bibr127-11786469231211184] 127. Wang FH, Liu J, Deng QJ, et al. Association between plasma essential amino acids and atherogenic lipid profile in a Chinese population: a cross-sectional study. Atherosclerosis. 2019;286:7-13. [DOI] [PubMed] [Google Scholar]

[bibr128-11786469231211184] 128. Wang SM, Yang RY, Wang M, et al. Identification of serum metabolites associated with obesity and traditional risk factors for metabolic disease in Chinese adults. Nutr Metab Cardiovasc Dis. 2018;28:112-118. [DOI] [PubMed] [Google Scholar]

[bibr129-11786469231211184] 129. Widner B, Leblhuber F, Walli J, et al. Tryptophan degradation and immune activation in Alzheimer’s disease. J Neural Transm. 2000;107:343-353. [DOI] [PubMed] [Google Scholar]

[bibr130-11786469231211184] 130. Wu D, Chen M, Chen S, et al. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis. Clin Rheumatol. 2022;41:3107-3117. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr131-11786469231211184] 131. Wu Y, Mai N, Weng X, Liang J, Ning Y. Changes of altruistic behavior and kynurenine pathway in late-life depression. Front Psychiatry. 2020;11:338. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr132-11786469231211184] 132. Wu Y, Zhong X, Mai N, et al. Kynurenine pathway changes in late-life depression. J Affect Disord. 2018;235:76-81. [DOI] [PubMed] [Google Scholar]

[bibr133-11786469231211184] 133. Xu HB, Fang L, Hu ZC, et al. Potential clinical utility of plasma amino acid profiling in the detection of major depressive disorder. Psychiatry Res. 2012;200: 1054-1057. [DOI] [PubMed] [Google Scholar]

[bibr134-11786469231211184] 134. Yan J, Kuzhiumparambil U, Bandodkar S, Solowij N, Fu S. Development and validation of a simple, rapid and sensitive LC-MS/MS method for the measurement of urinary neurotransmitters and their metabolites. Anal Bioanal Chem. 2017;409:7191-7199. [DOI] [PubMed] [Google Scholar]

[bibr135-11786469231211184] 135. Yao JK, Dougherty Gg, Jr, Reddy RD, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010;15:938-953. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr136-11786469231211184] 136. Yilmaz A, Ugur Z, Bisgin H, et al. Targeted metabolic profiling of urine highlights a potential biomarker panel for the diagnosis of Alzheimer’s disease and mild cognitive impairment: a pilot study. Metabolites. 2020;10:357. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr137-11786469231211184] 137. Yoshitake M, Nohta H, Ogata S, et al. Liquid chromatography method for detecting native fluorescent bioamines in urine using post-column derivatization and intramolecular FRET detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:307-312. [DOI] [PubMed] [Google Scholar]

[bibr138-11786469231211184] 138. Zhang Z, Zhang M, Luo Y, et al. Preliminary comparative analysis of kynurenine pathway metabolites in chronic ketamine users, schizophrenic patients, and healthy controls. Hum Psychopharmacol. 2020;35:e2738. [DOI] [PubMed] [Google Scholar]

[bibr139-11786469231211184] 139. Zhao J, Chen H, Ni P, et al. Simultaneous determination of urinary tryptophan, tryptophan-related metabolites and creatinine by high performance liquid chromatography with ultraviolet and fluorimetric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879:2720-2725. [DOI] [PubMed] [Google Scholar]

[bibr140-11786469231211184] 140. Zhen Q, Xu B, Ma L, et al. Simultaneous determination of tryptophan, kynurenine and 5-hydroxytryptamine by HPLC: application in uremic patients undergoing hemodialysis. Clin Biochem. 2011;44:226-230. [DOI] [PubMed] [Google Scholar]

[bibr141-11786469231211184] 141. Zhou S, Huang Y, Kuang Q, et al. Kynurenine pathway metabolites are associated with gray matter volume in subjects with schizophrenia. Front Psychiatry. 2022;13. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr142-11786469231211184] 142. Zhou Y, Zheng W, Liu W, et al. Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder. Psychoneuroendocrinology. 2019;101:72-79. [DOI] [PubMed] [Google Scholar]

[bibr143-11786469231211184] 143. Hampel H, O’Bryant SE, Durrleman S, et al.; for the Alzheimer Precision Medicine Initiative. A precision medicine initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling. Climacteric. 2017; 20:107-118. [DOI] [PubMed] [Google Scholar]

[bibr144-11786469231211184] 144. Reitz C. Toward precision medicine in Alzheimer’s disease. Ann Transl Med. 2016;4:107. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr145-11786469231211184] 145. Züllig T, Köfeler HC. High resolution mass spectrometry in lipidomics. Mass Spectrom Rev. 2021;40:162-176. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr146-11786469231211184] 146. Chen C, Hou J, Tanner JJ, Cheng J. Bioinformatics methods for mass spectrometry-based proteomics data analysis. Int J Mol Sci. 2020;21:2873. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr147-11786469231211184] 147. Jove M, Spencer J, Clench M, Loadman PM, Twelves C. Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistance. Crit Rev Oncol Hematol. 2019;141:153-162. [DOI] [PubMed] [Google Scholar]

[bibr148-11786469231211184] 148. Churchwell MI, Twaddle NC, Meeker LR, Doerge DR. Improving LC-MS sensitivity through increases in chromatographic performance: comparisons of UPLC-ES/MS/MS to hplc-es/ms/ms.-ES. J Chromatogr B. 2005;825: 134-143. [DOI] [PubMed] [Google Scholar]

[bibr149-11786469231211184] 149. Slavík J. Absorption spectroscopy. Intracellular pH and Its Measurement. 1989:69. [Google Scholar]

[bibr150-11786469231211184] 150. Fukunaga Y, Katsuragi Y, Izumi T, Sakiyama F. Fluorescence characteristics of kynurenine and N′-formylkynurenine, their use as reporters of the environment of tryptophan 62 in hen egg-white lysozyme1. J Biochem. 1982;92:129-141. [DOI] [PubMed] [Google Scholar]

[bibr151-11786469231211184] 151. Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacol. 2017;112:248-263. [DOI] [PubMed] [Google Scholar]

[bibr152-11786469231211184] 152. Ninomiya S, Nakamura N, Nakamura H, et al. Low levels of serum tryptophan underlie skeletal muscle atrophy. Nutrients. 2020;12:978. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr153-11786469231211184] 153. Murr C, Grammer TB, Kleber ME, et al. Low serum tryptophan predicts higher mortality in cardiovascular disease. Eur J Clin Invest. 2015;45:247-254. [DOI] [PubMed] [Google Scholar]

[bibr154-11786469231211184] 154. Zhang A, Sun H, Wang X. Saliva metabolomics opens door to biomarker discovery, disease diagnosis, and treatment. Appl Biochem Biotechnol. 2012;168:1718-1727. [DOI] [PubMed] [Google Scholar]

[bibr155-11786469231211184] 155. Khamis MM, Adamko DJ, El-Aneed A. Mass spectrometric based approaches in urine metabolomics and biomarker discovery. Mass Spectrom Rev. 2017;36: 115-134. [DOI] [PubMed] [Google Scholar]

[bibr156-11786469231211184] 156. Miller RC, Brindle E, Holman DJ, et al. Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations. Clin Chem. 2004;50:924-932. [DOI] [PubMed] [Google Scholar]

[bibr157-11786469231211184] 157. Ağagündüz D, Kocaadam-Bozkurt B, Bozkurt O, et al. Microbiota alteration and modulation in Alzheimer’s disease by gerobiotics: the gut-health axis for a good mind. Biomed Pharmacother. 2022;153. [DOI] [PubMed] [Google Scholar]

[bibr158-11786469231211184] 158. Jacobs KR, Lim CK, Blennow K, et al. Correlation between plasma and CSF concentrations of kynurenine pathway metabolites in Alzheimer’s disease and relationship to amyloid-β and tau. Neurobiol Aging. 2019;80:11-20. [DOI] [PubMed] [Google Scholar]

[bibr159-11786469231211184] 159. Székely G, Henriques B, Gil M, Alvarez C. Experimental design for the optimization and robustness testing of a liquid chromatography tandem mass spectrometry method for the trace analysis of the potentially genotoxic 1,3-diisopropylurea. Drug Test Anal. 2014;6:898-908. [DOI] [PubMed] [Google Scholar]

[bibr160-11786469231211184] 160. Chaleckis R, Meister I, Zhang P, Wheelock CE. Challenges, progress and promises of metabolite annotation for LC-MS-based metabolomics. Curr Opin Biotechnol. 2019;55:44-50. [DOI] [PubMed] [Google Scholar]

[bibr161-11786469231211184] 161. Solvang SH, Hodge A, Watne LO, et al. Kynurenine pathway metabolites in the blood and cerebrospinal fluid are associated with human aging. Oxid Med Cell Longev. 2022;2022:5019752. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr162-11786469231211184] 162. Lassen JK, Wang T, Nielsen KL, et al. Large-scale metabolomics: predicting biological age using 10,133 routine untargeted LC-MS measurements. Aging Cell. 2023;22:e13813. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr163-11786469231211184] 163. Guo L, Zhong MB, Zhang L, Zhang B, Cai D. Sex differences in Alzheimer’s disease: Insights from the multiomics landscape. Biol Psychiatry. 2022;91:61-71. [DOI] [PMC free article] [PubMed] [Google Scholar]

[bibr164-11786469231211184] 164. Mor A, Tankiewicz-Kwedlo A, Krupa A, Pawlak D. Role of kynurenine pathway in oxidative stress during neurodegenerative disorders. Cells. 2021;10:1603. [DOI] [PMC free article] [PubMed] [Google Scholar]

PERMALINK

Normative Data on Serum and Plasma Tryptophan and Kynurenine Concentrations from 8089 Individuals Across 120 Studies: A Systematic Review and Meta-Analysis

Najwa-Joelle Metri

Ali S Butt

Ava Murali

Genevieve Z Steiner-Lim

Chai K Lim

Abstract

Introduction

Methods and Materials

Study protocol

Search strategy

Table 1.

Study selection

Eligibility criteria

Data extraction

Risk of bias evaluation

Statistical analyses

Results

Figure 1.

Study characteristics

Risk of bias evaluation and method validation

Table 2.

Table 3.

Analysis of variance

Table 4.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Regression analyses

Table 5.

Non-blood sample matrices

Table 6.

Discussion

Supplemental Material

Footnotes

References

Associated Data

Supplementary Materials

ACTIONS

PERMALINK

RESOURCES

Similar articles

Cited by other articles

Links to NCBI Databases